Allard, Michael

Allard, Michael

Allard, Michael

BSc, MD, FRCP(C)

Academic Rank(s): Professor Emeritus, Department of Pathology and Laboratory Medicine, UBC | Vice-Dean, Health Engagement, Centre for Heart Lung Innovation (HLI)

Affiliation(s): St. Paul’s Hospital / HLI

Research and Scholarly Interests: Cardiovascular and Pulmonary, Endocrinology, Metabolism & Nutrition, Control of Energy Metabolism in Normal and Pathologic Hearts, Physiologic and Pathologic Cardiac Hypertrophy, Contribution of Metabolism to Myocardial Dysfunction after Ischemia and Reperfusion especially in the setting of Cardiac Hypertrophy, Cardiovascular Pathology

Clinical Interests:

Short Bio
OpenClose

Dr. Mike Allard was appointed Professor Emeritus in 2025.

 

Academic
OpenClose

Academic Background

  • UBSc (Biology), University of British Columbia 1974-1978
  • MD (Medicine), University of British Columbia 1977-1981
  • Residency, Anatomic Pathology, University of British Columbia 1983-1988
  • Certification in Anatomic Pathology, Royal College of Physicians & Surgeons of Canada, FRCP(C), 1988
  • Research Fellow (Pulmonary Research), Pulmonary Research Laboratory, University of British Columbia 1985-1987
  • Research Fellow (Cardiovascular Pathology), University of Alabama at Birmingham 1988-1990

Awards and Recognition

Publications

Dr. Michael Allard PUBMED

Selected Publications

Research
OpenClose

Research Interest

  • Control of energy metabolism in normal and pathologic hearts
  • Physiologic and Pathologic Cardiac hypertrophy
  • Contribution of Metabolism to myocardial dysfunction after ischemia and reperfusion, especially in the setting of cardiac hypertrophy
  • Cardiovascular Pathology

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Aparicio, Samuel

Aparicio, Samuel

BM BCh PhD FRCPath FRSC

Academic Rank(s): Professor, UBC, Distinguished Scientist, Department Head, Molecular Oncology, BCCA

Affiliation(s): BC Cancer/BCCRC

Research and Scholarly Interests: Genomics, evolution, single cell biology, functional genomics, computational methods, drug development, genomic instability, breast cancer, ovarian cancer, osteosarcoma

Clinical Interests: Integrating genomic studies with clinical trials, selection and drug response, mutational signatures in DNA repair deficient cancers, single cell genomics of cancer

Short Bio
OpenClose

Dr. Samuel Aparicio (BM, BCh, PhD, FRCPath, FRSC) is the Nan & Lorraine Robertson Chair in Breast Cancer Research, holds the Canada Research Chair (Tier 1) in Molecular Oncology, and is the recipient of the 2014 Aubrey J Tingle Prize. He is also Head of the Department of Breast and Molecular Oncology at BC Cancer Research, part of the Provincial Health Services Authority, and a Professor in the Department of Pathology and Laboratory Medicine at UBC.

Dr. Aparicio graduated in medical and natural sciences from Cambridge University (UK), clinical medicine from Oxford, and subsequently in internal medicine and pathology. After doctoral work with Sydney Brenner in Cambridge, he held a Wellcome Trust Career Development Fellowship at the Wellcome/CRUK Developmental Biology Institute. From 2000-2005 he was a senior investigator in the Department of Oncology, Cambridge. He was a co-leader of the international consortium that sequenced the genome of the pufferfish Fugu rubripes in 2002. He moved to Vancouver in 2005.

Affiliations

Faculty member, UBC Genome Science and Technology Graduate Program
Associate member, Head Single Cell Genomics, BC Cancer Genome Sciences Centre
Associate member, UBC CIHR/MSFHR Bioinformatics Program
Associate member, Michael Smith Genome Sciences Centre

Credentials

Professor, University of British Columbia – Department of Pathology and Laboratory Medicine
Canada Research Chair in Molecular Oncology
Department Head , BC Cancer, Department of Molecular Oncology
Nan & Lorraine Robertson Chair of Breast Cancer Research, UBC/BC Cancer
Affiliate Member, New York Genome Center
Associate Member, BC Cancer, Genome Sciences Center
Affiliated Investigator, Vancouver Coastal Health Authority
Distinguished Scientist, BC Cancer, Department of Molecular Oncology
PhD, University of Cambridge

Links

 

Academic
OpenClose

Academic Background

  • Royal College of Pathologists, MRC Pathology. May 2004
  • PhD, University of Cambridge, UK. 1995
  • MA, University of Cambridge, UK (Comparative gene regulation). 1988
  • BM BCh, University of Oxford, UK (Clinical Medicine). 1988
  • BA, University of Cambridge, UK (Natural and Medical Sciences). 1985/12

Awards and Recognition

Publications

Dr. Samuel Aparicio ORCID

Research
OpenClose

Research Interest

Dr. Aparicio’s research program encompasses the fields of cancer genomics, mouse genetic models, high throughput screens, small molecule chemical probes and translational breast cancer research. His most recent work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed, and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype. Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Contextual Genomics Ltd. He was elected to the Royal Society of Canada in 2016 and is honoured as a University of British Columbia Distinguished University Scholar (2017). His contributions to academic research have been widely published in scientific and clinical journals such as Nature, Science, Cell and the New England Journal of Medicine. He is the recipient of numerous awards from academic as well as industrial institutions.

  • Breast cancer genome sequencing
    Discovery of novel gene mutations
  • Breast cancer xenografts
    Pre-clinical models of breast tumour biology and drug response
  • Cancer epigenetics
    Investigation of non-sequence changes to tumour cell DNA
  • Characterisation of normal and cancerous mammary stem cells  Discovery of genes involved in stem cell proliferation and differentiation
  • Genetic heterogeneity within breast tumours and single cell genomics  Identification and characterisation of tumour cell subpopulations
  • Induced pluripotent stem (iPS) cells  Development of novel methods to help move iPS cells into the clinic
  • Mammographic density and columnar cell lesions of the breast  Investigation of the connection between common breast cell abnormalities and the higher risk of tumour development in dense breast tissue
  • METABRIC
    Molecular classification of breast cancer subtypes
  • Screening the human genome for genes involved in breast cancer  Discovery of novel gene-gene and gene-drug interactions

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Bally, Marcel

Bally, Marcel

BSc, MSc (Texas), PhD (Brit. Col.)

Academic Rank(s): Professor, Department of Pathology & Laboratory Medicine, Faculty of Medicine, UBC, Head and Distinguished Scientist, Department of Experimental Therapeutics, BC Cancer

Affiliation(s): BC Cancer

Research and Scholarly Interests: Drug development, drug delivery, cancer, lipid-based formulations, liposomes, lipid nanoparticles, good manufacturing practices, good laboratory practices, biochemistry, academic IP and commercialization

Clinical Interests: Translating basic research into clinical products that improve patient care, including involvement in the creation of biotechnology companies that bring these innovations to market.

Short Bio
OpenClose

Dr. Bally is a recognized expertise in biochemistry, pharmacology/ toxicology, nanoscale drug delivery formulations and preclinical models including expertise in a variety of orthotopic and metastatic cancer models as well as pharmacodynamic analysis. He is qualified to conduct preclinical safety studies under Good Laboratory Practices and has completed training in Good Manufacturing Practices. He has trained over 60 PDFs/PhD students. Trainees currently in his lab have competitive salary support from MITACs and the Brazil government. Of those which have moved on from his lab, 10 are in tenured academic positions, 17 hold management and scientific posts in biotech companies, 4 are involved in regulatory affairs, 11 are physicians and 6 work in organizations that form an interface between industry and academia (e.g. Centre for Drug Research and Development, CDRD). He co-founded CDRD, an organization which translates academic discoveries into commercially viable technologies.

Dr. Bally’s research has resulted in >200 peer reviewed papers, >140 published abstracts, 21 book chapters, and >200 patents. Google Scholar indicates that his collective works has >22,000 citations, 250 of these have been cited >10 times. His lifetime H-index is currently 77 and since 2014 his H-index is 43. The majority of his publications appear in the top 10% of journals listed within identified SJR Subject Area Rankings. His productivity includes: (i) creation of start-up companies; (ii) publication and patents that have transformed the field of lipid-based drug delivery; (iii) an ability to sustain continuous grant funding for >25 years; (iv) mentorship of trainees who develop successful careers; and (v) development of products that benefit patients with cancer. He has advanced the field of nanotechnology by pioneering novel manufacturing, drug loading, and freeze-drying methods as well as by discovering novel compositions that define approved drugs (e.g. MyoCetTM; marketed by Teva Pharmaceuticals and MarqiboTM; marketed by Spectrum Pharmaceuticals) as well as a drug combination that may replace the standard of care for patients with high risk AML (VYXEOS™; marketed by Jazz Pharmaceuticals). Marqibo has only recently been approved so its impact on cancer patients is too early to judge; but large-scale meta-analysis of data from metastatic breast cancer patients in Europe treated with MyoCet prove that it is a safer alternative to doxorubicin. He co-invented technologies protecting fixed ratio drug combination products such as VYXEOS™. Recently he has patented the use of metal complexation reactions to associate metal complexing water soluble drugs with lipid based nanoparticulate formulations; a technology base that is currently being expanded to include water insoluble metal complexed drugs. Four companies that he co-founded (Inex-renamed Arbutus Biopharm, Northern Lipids-renamed Transferra (acquired by Evonik), Celator (acquired by Jazz Pharmaceuticals) and Cuprous Pharmaceuticals) are still operating and when considered with CDRD, these organizations employ >250 FTEs in BC. Transferra was acquired by Evonik for $43M/Cdn and Celator was acquired by Jazz for $1.5B/Cdn. Since its introduction VYXEOS™ resulted in over $180 million US in sales world wide.

Affiliations

  • Head and Distinguished Scientist, Department of Experimental Therapeutics, BC Cancer
  • Member, Centre for Blood Research, UBC
  • Professor, Pathology & Laboratory Medicine, UBC
  • Adjunct Professor, Pharmaceutical Sciences, UBC
Academic
OpenClose

Academic Background

  • MRC Centennial Fellow, Biochemistry – U.B.C
  • MRC Postdoctoral Fellow, Terry Fox Laboratory – BC Cancer Agency
  • PhD (Biochemistry), UBC, 1984
  • MSc (Biol.), Texas A&M University, 1979
  • BSc (Biol.), Texas A&M University, 1977

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

The research conducted in my laboratory focuses on developing improved protocols for the treatment of cancer. Clinicians have an arsenal of very potent drugs available for treatment of cancer. These drugs, however, lack specificity and often produce severe, life threatening, toxicities. Further, optimal therapeutic effects of any anticancer drug appear to be dependent on their use in a combination setting. Multi-agent therapy is the standard by which cancer is treated. Based on this understanding, research in my laboratory is designing methods and strategies for capturing the benefits of drug combination effects that are often first measured using cell based screening assays. Although basic research interests include evaluation of novel targeted anticancer drugs, my group is also comprehensively pursuing combinations of existing, already approved, cytotoxic agents. The latter studies will provide the proof of concept data needed to demonstrate the value of pursuing anticancer drug combination products. These products will be of particular interest when used with emerging targeted agents, but will also demonstrate the potential to develop new products that may consist of two or more targeted agents.

In order to achieve this, my research group embraces two fundamental principles: (i) drug combination products will be dependent on use of drug carrier technologies and (ii) drug combination products should achieve optimal therapeutic effects using better tolerated drug doses. I have extensive expertise on the use of liposome drug carriers for improving the specificity of anti-cancer drugs as well as enabling the use of some exciting new biologically active agents, such as therapeutically active antibodies, nucleic acid drugs (antisense oligonucleotides and siRNA) and therapeutically active peptides. In general terms, liposomes are small microscopic bags prepared from natural and synthetic lipids (fats). The therapeutic activity of conventional anti-cancer drugs can be improved, sometimes dramatically, when given intravenously trapped inside these lipid bags. Mechanistically, it has been suggested that liposomal drugs deliver more drug to tumors then conventional drug and development of this technology has been based on achieving improvements in drug delivery to sites of cancer growth. It is believed that delivery of liposomal drug carriers from the blood to interstitial sites within the tumor is due to characteristics of tumor blood vessels. In addition, my research clearly establishes that drug release from liposomes, whether in the blood compartment or within the tumor, can increase tumor cell exposure to anticancer drugs. Based on this understanding, my lab is now using drug carriers, such as liposomes, to provide the format to deliver combinations of drugs that are shown, via high content cell screening assays, to interact to achieve better than expect (synergistic) therapeutic activity.

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Path 301, section of bioenergetics

Path 438, Course Coordinator

Path 521, Course Coordinator

Anat 527, Course Coordinator

Churg, Andrew

Churg, Andrew

MD, PhD

Academic Rank(s):Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine, UBC

Affiliation(s): VGH and Institute for Heart + Lung Health

Research and Scholarly Interests: Cardiopulmonary, including pathologic investigation of mesothelioma diagnosis and interstitial lung disease diagnosis

Clinical Interests: Thoracic pathology, including the diagnosis of malignant mesothelioma, distinguishing between benign and malignant mesothelial proliferations, and the classification of interstitial lung diseases

Short Bio
OpenClose

Dr. Churg is a Professor of Pathology at the University of British Columbia and a pathologist at Vancouver General Hospital in Vancouver, BC. He is the author of more than 500 publications dealing with all aspects of thoracic pathology, including the 4th series Fascicle: Tumors of the Serosal Membranes, and Atlas of Interstitial Lung Disease Pathology. His areas of special interest are the diagnosis of malignant mesothelioma, the separation of benign from malignant mesothelial proliferations, and the diagnosis and classification of interstitial lung disease.

Academic
OpenClose

Academic Background

  • Postdoctoral Fellowship, Pulmonary Pathology, Stanford University. 1977-1978
  • Internship and Residency, Pathology, University of Chicago. 1973-1977
  • MD, University of Chicago, Medicine. 1973
  • PhD, University of Chicago, Pathology. 1971
  • AB, Columbia University, NY, Chemistry. 1967

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

  • Pathology of occupational lung disease: diagnosis and mechanisms
  • Cardiovascular & Pulmonary disease
  • Lungs and Breathing

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dorovini-Zis, Katerina

Dorovini-Zis, Katerina

MD, FRCPC

Academic Rank(s): Professor Emerita, Pathology and Laboratory Medicine, UBC |

Affiliation(s): VGH/VCHRIICORD Research Center

Research and Scholarly Interests: Brain and Neuroscience, Infectious Diseases and Immunology Microbiology

Clinical Interests:

Short Bio
OpenClose

Katerina Dorovini-Zis, MD, FRCPC, is Professor Emerita of Pathology and Laboratory Medicine at the University of British Columbia. Dr. Dorovini-Zis earned her M.D. degree from the National University of Athens, Greece. She completed a residency in anatomical pathology and neuropathology at Vancouver General Hospital. After a research fellowship at the National Institutes of Neurological Disorders and Stroke, NIH, supported by a Fogarty Fellowship (1977-1980), she joined the faculty of the University of Michigan in 1980. She joined the faculty of the University of British Columbia in 1985. She worked as Consultant Neuropathologist at Vancouver General Hospital and served as Head of the Division of Neuropathology from 1994 to 2007. She was the director of the Neuropathology Research Laboratory from 1985 to 2018.

 

Academic
OpenClose

Academic Background

  • National University of Athens MD. 1969
  • Residency in Anatomical Pathology (VGH) and Neuropathology (VGH) 1971-1976
  • Fogarty Fellowship, NINDS, N.I.H. 1977-1980

Dr. Dorovini-Zis has held memberships with many organizations. She has served on grant review committees for the Multiple Sclerosis Society of Canada, the Canadian Heart and Stroke Foundation and the Alberta Health Foundation for Medical Research, as editorial board member in several journals and as ad hoc reviewer for numerous scientific journals and granting agencies. She has authored and co-authored over 70 publications, several book chapters and published two books on the Blood-Brain Barrier in Health and Disease.

Awards and Recognition

  • Teacher Investigator Award, NINDS, N.I.H. 1982-85
  • Women in Neuroimmunology Award. 1998
  • Honorable Mention-Weil Award for Best Paper in Experimental Neuropathology. 1998
  • David Hardwick Life Time Achievement Award, UBC Department of Pathology, 2012.

Publications

Selected Publications

  • Dorovini-Zis K, Stins M, Desruisseaux MS, Martins YC, van der Heyde H. The brain microvasculature in cerebral malaria. In: The Blood- Brain Barrier in Health and Disease. Volume 2: Pathophysiology and Pathology. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2016, pp 68-117.
  • Dorovini-Zis K. (Editor). The Blood-Brain Barrier in Health and Disease. Volume 2: Pathophysiology and Pathology. CRC Press, Boca Raton, FL, USA. 2016.
  • Dorovini-Zis K. (Editor). The Blood-Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. CRC Press, Boca Raton, FL, USA. 2015.
  • Dorovini-Zis K, Nag S. Morphological and functional properties of the blood-brain barrier. In: The Blood- Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2015, pp 1-50.
  • Dorovini-Zis K, Easton A. Inflammatory mediators and the blood-brain barrier. In: The Blood- Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2015, pp 239-288.
  • Dorovini-Zis K. Endothelial surface-associated molecules of relevance to the immune function of the blood-brain barrier. In: The Blood- Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2015, pp 289-330.
  • Quandt J, Dorovini-Zis K. Chemokines as mediators of leukocyte trafficking and activation at the blood-brain barrier. In: The Blood- Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2015, pp331-355.
  • Dorovini-Zis K, Wong D, Liu K. Leukocyte entry into the brain. In: The Blood- Brain Barrier in Health and Disease. Volume 1: Morphology, Biology and Immune Function. Dorovini-Zis K (Ed), CRC Press, Boca Raton, FL, USA, 2015, pp356-403.
  • Greiner J, Dorovini-Zis K. Taylor TE, Molyneux ME, Beare NAV, Kamiza S, White VA. Correlation of hemorrhage, axonal damage and blood-tissue barrier disruption in brain and retina of Malawian children with fatal cerebral malaria. FCIMB 2015 Mar 16;5:18. doi: 10.3389/fcimb.2015.00018.
  • Zis O, Zhang S, Dorovini-Zis K, Wang L, Song W. Hypoxia signaling regulates macrophage migration inhibitory factor (MIF) expression in stroke. Mol. Neurobiol. 2015 Feb.51(1):155-167.
  • Liu KYK, Dorovini-Zis, K. Differential regulation of CD4+ T cell adhesion to cerebral microvascular endothelium by the b-chemokines CCL2 and CCL3. Int. J. Mo.l Sc. 2012:13:16119-40. PMID:23203188.
  • Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, Kamiza S, Molyneux M, Taylor TE. The Neuropathology of fatal cerebral malaria in Malawian children. Am. J. Pathology.2011 May;178 (5):2146-58.
  • Casiraghi C, Dorovini-Zis K, Horwitz MS. Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol. 2011 Jan;230(1-2):173-7.
  • Chui R, Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation. 2010 Jan 4;7:1. Jan 2010
  • Liu KK, Dorovini-Zis K. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration. J Neuroimmunol. 2009 Oct 30;215(1-2):49-64.
  • Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, Kamiza S, Molyneux M, Taylor TE. The Neuropathology of fatal cerebral malaria in Malawian children. Am. J. Pathology.2011 May;178 (5):2146-58.
  • Casiraghi C, Dorovini-Zis K, Horwitz MS. Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol. 2011 Jan;230(1-2):173-7.
  • Chui R, Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation. 2010 Jan 4;7:1. Jan 2010
  • Liu KK, Dorovini-Zis K. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration. J Neuroimmunol. 2009 Oct 30;215(1-2):49-64.
  • Arjmandi A, Liu K, Dorovini-Zis K. Dendritic cell adhesion to cerebral endothelium: role of endothelial cell adhesion molecules and their ligands. J Neuropathol Exp Neurol. 2009 Mar;68(3):300-13.
Research
OpenClose

Research Interest

Dr. Dorovini-Zis’ primary research interest is to understand the mechanisms of leukocyte recruitment across the blood-brain barrier in central nervous system inflammation, focusing on the role of the cerebral endothelium as an active participant in this process. Upon founding her independent Neuropathology Research Laboratory in 1985, she established the first in vitro model of the human blood-brain barrier that mimics the blood-brain barrier in vivo. This model has been used in her laboratory to investigate the mechanisms that support adhesion and migration of different leukocyte subtypes (lymphocytes, monocytes, neutrophils, dendritic cells) across the blood-brain barrier and determine the effects of inflammatory mediators on barrier permeability and on how endothelial-derived adhesion molecules, class II MHC, costimulatory molecules and chemokines mediate leukocyte-endothelial cell interactions at the human blood-brain barrier. Her interests extend to the study of blood-brain barrier dysfunction in infectious and inflammatory CNS diseases with particular emphasis on the mechanisms responsible for blood-brain barrier dysfunction and brain damage in pediatric cerebral malaria.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dr. Dorovini-Zis has been actively involved in undergraduate, graduate and post-graduate teaching and in the primary supervision of PhD, MSc, visiting, undergraduate students and post-doctoral fellows.

Gilks, Blake

Gilks, Blake

MD, FRCPC

Academic Rank(s): Professor Emeritus, Pathology and Laboratory Medicine, UBC | Co-Founder, Ovarian Cancer Research Program (OVCARE)

Affiliation(s): VGH/VCHRI

Research and Scholarly Interests: Breast and Gynecological Pathology, Cancer

Clinical Interests:

Short Bio
OpenClose

Blake is a Professor Emeritus in the Dept of Pathology and Laboratory Medicine, at the University of British Columbia. He leads a research program focused on gynecological cancers. He was lead pathologist on studies refining the histotype-based classification of ovarian carcinoma, molecular classification of endometrial carcinoma, and etiology-based classification of vulvar carcinoma, and was part of the team that championed opportunistic salpingectomy to prevent tubo-ovarian high grade serous carcinoma. He has been an author on more than 500 peer-reviewed publications, with more than 40,000 citations. He is co-founder and medical-director of the Canadian Pathology Quality Assurance program, which provides proficiency testing for Canadian diagnostic immunohistochemistry laboratories.

 

Academic
OpenClose

Academic Background

  • Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)
  • MD cum laude, Dalhousie University, Medicine. 1982
  • BSc, University of New Brunswick. 1978

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Breast and Gynecological Pathology
  • Teaching Pathology, Surgery and Obstetrics and Gynecology Residents
  • Development of Pathology labs for the GI/Nutrition block of the new medical school curriculum
  • Cancer

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Huntsman, David

Huntsman, David

MD, FRCPC, FCCMG

Academic Rank(s): Professor, Department of Pathology and Laboratory Medicine and Obstetrics and Gynaecology, Faculty of Medicine, UBC | Director Of Ovcare & Distinguished Scientist

Affiliation(s): BC Cancer

Research and Scholarly Interests: Cancer Genomics, Digital Pathology, Genomic Pathology, Molecular Diagnostics, Ovarian Cancer, Rare Tumours

Clinical Interests: Dr. Huntsman is involved in clinical activities related to cancer genetics and the development of new diagnostic methods for cancer, particularly those affecting the ovaries.

Short Bio
OpenClose

Dr. David Huntsman is a Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at The University of British Columbia (UBC) and is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology. He is a a Staff Pathologist at the BC Cancer, a part of the Provincial Health Services Authority, and a Consulting Pathologist at the Vancouver General Hospital (VGH). Dr. Huntsman is currently the Director of the BC multidisciplinary ovarian cancer research team (OvCaRe), Medical Director of the Centre for Translational and Applied Genomics (CTAG) at the BC Cancer, and co-Director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH.

Dr. Huntsman research has led to development of predictive and prognostic tissue based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for subtype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer. As collaboration is critical in his field, Dr. Huntsman happily leads and engages in a wide number of multidisciplinary research groups. Most recently he has been working on the creation of broad based personalized medicine initiative for British Columbia.


Affiliations

OVCARE
UBC Department of Pathology
UBC Department of Obstetrics and Gynecology
Vancouver Coastal Health Research Institute
UBC Genome Science and Technology Graduate Program
UBC and BC Cancer Interdisciplinary Oncology Program
CIHR/MSFHR Bioinformatics Program

Credentials

Professor, Department of Pathology & Laboratory Medicine and Obstetrics & Gynaecology, University of British Columbia
Dr. Chew Wei Memorial Professor of Gynaecologic Oncology, University of British Columbia
Canada Research Chair in Molecular and Genomic Pathology
Director of OVCARE, Vancouver General Hospital, BC Cancer and University of British Columbia
Distinguished Scientist, Department of Molecular Oncology, BC Cancer Research Centre
Director of the Molecular Pathology Laboratory, Vancouver General Hospital
Associate Member, BC Cancer, Genome Sciences Center
Associate Member, University of British Columbia, Department of Medical Genetics
Associate Member, University of British Columbia, Department of Urologic Sciences
Associate Member, University of British Columbia, CIHR/MSFHR Bioinformatics Program
Associate Member, University of British Columbia and BC Cancer, Interdisciplinary Oncology Program
Associate Member, University of British Columbia, Genome Science and Technology Graduate Program
MD, Memorial University of Newfoundland 1988
Rotating Internship, Dalhousie University 1989
Pathology Residency, University of British Columbia 1995
Clinical Oncology and Cancer Genetics Fellowship, University of Cambridge 1999

Academic
OpenClose

Academic Background

  • FRCPC. 1995
  • MD – Memorial University Newfoundland, Canada. 1988

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

Dr. David Huntsman’s research interests are centered around the molecular characterization and treatment of ovarian and other gynecological cancers. He focuses on identifying and understanding the genetic drivers of these cancers to develop better diagnostic tools and targeted therapies. His work includes studying rare ovarian cancer subtypes and exploring the genetic mutations that influence cancer behavior and treatment outcomes.

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Karsan, Aly

Karsan, Aly

BA, MD (Queen’s)

Academic Rank(s): Professor, Distinguished Scientist, Pathology and Laboratory Medicine, UBC | Staff Pathologist and Program Medical Director, Provincial Pathology & Laboratory Medicine, BC Cancer

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Blood research, Cancer, Genetics genomics proteomics and related approaches, Human Development and Aging, Molecular Pathology and Cell Biology, Professional Contributions

Clinical Interests:

Short Bio
OpenClose

Karsan Lab. We are located at the Michael Smith Genome Sciences Centre, part of the BC Cancer Research Centre.

After receiving his MD from Queen’s University in Kingston, Ontario and a rotating internship at Lion’s Gate Hospital, North Vancouver, BC, Dr. Karsan practiced medicine in rural BC and the Northwest Territories before working as a volunteer with Médecins Sans Frontières. He then completed his residency in Hematological Pathology at the University of British Columbia (UBC) followed by a Research Fellowship at the University of Washington.

Currently, Dr. Karsan is Professor of Pathology and Laboratory Medicine at UBC, and Distinguished Scientist at Canada’s Michael Smith Genome Sciences Centre at BC Cancer. Dr. Karsan has been supported by several prestigious awards over the years, including 10 years as a Clinician-Scientist awardee of the Canadian Institutes of Health Research, 10 years as a Scholar of the Michael Smith Foundation of Health Research and currently as the recipient of the John Auston BC Cancer Foundation Clinical Scientist Award.

Dr. Karsan is internationally recognized in the field of blood cancer research. His translational research lab has generated seminal work on the role of noncoding RNAs and innate immune signaling in blood cancers. He currently leads a team of six principal investigators in a Terry Fox Research Institute Program Project in acute leukemia research. He is a member of various international hematology committees including: the International Working Group for Prognosis in Myelodysplastic Syndromes (MDS), the Experimental Hematology Subcommittee of the Society for Hematopathology, and the Laboratory Assays Working Group for the Myeloid Malignancies Precision Medicine Initiative. In 2002, he co-founded the Centre for Blood Research at UBC with nine other principal investigators.

Dr. Karsan is also a recognized leader in delivering clinical genomic assays. He established the first clinically-accredited Next Generation Sequencing lab in Canada, the Centre for Clinical Genomics (CCG), which was among the first few in the world. The CCG delivers cancer genomic testing to the entire population of BC. This pioneering work in using next generation sequencing (NGS) technologies for clinical delivery has led to the development of various novel technologies for clinical genomic testing including a unique genetic barcoding system to track patient samples, development and implementation of clinical reporting software for NGS, development of a transcriptomic (RNA sequencing) test for leukemia and clinical validation of a non-invasive prenatal test (NIPT) by whole genome sequencing in partnership with the Prenatal Screening Program of BC. He has led clinical trials in leukemia and solid tumour genomics and hereditary cancer diagnostics. These innovations led to a reduction of wait times for hereditary cancer testing, reduced per test costs and have increased the breadth of genes being tested. His work has been recognized with the Health Employers Association of BC (HEABC) Gold Apple award for Innovation.

Affiliations
  • Professor, Department of Pathology and Laboratory Medicine, University of British Columbia
  • Member, Experimental Medicine, University of British Columbia
  • Founding Member, Centre for Blood Research, University of British Columbia
  • Member, Stem Cell Network
Credentials

After receiving his MD from Queen’s University in Kingston, Ontario and a rotating internship at Lion’s Gate Hospital, North Vancouver, BC, Dr. Karsan practiced medicine in rural BC and the Northwest Territories before working as a volunteer with Médecins Sans Frontières. He then completed his residency in Hematological Pathology at the University of British Columbia (UBC) followed by a Research Fellowship at the University of Washington.

Currently, Dr. Karsan is Professor of Pathology and Laboratory Medicine at UBC, and Distinguished Scientist at Canada’s Michael Smith Genome Sciences Centre at BC Cancer. Dr. Karsan has been supported by several prestigious awards over the years, including 10 years as a Clinician-Scientist awardee of the Canadian Institutes of Health Research, 10 years as a Scholar of the Michael Smith Foundation of Health Research and currently as the recipient of the John Auston BC Cancer Foundation Clinical Scientist Award.

 

Academic
OpenClose

Academic Background

  • BA, Magna Cum Laude, Queen’s University, Kingston, ON, Life Sciences
  • University of St. Andrews, Scotland, Exchange scholarship (Queen’s University)
  • MD, Queen’s University, Faculty of Medicine, Medicine
  • Fellow of the Royal College of Physicians and Surgeons of Canada – Hematological Pathology

Awards and Recognition

Publications

PUBMED: Karsan, Aly

Selected Publications

Research
OpenClose

Research Interest

The Karsan Lab focuses on two major areas:

  • Understanding the molecular basis of myeloid malignancies, in particular the preleukemic bone marrow failure conditions called myelodysplastic syndromes (MDS); and
  • Determining the role of the endothelium in the development of the hematopoietic system. With respect to both areas we have been studying the role of two pathways: innate immune signaling as represented by the Toll-like receptor (TLR) pathways, and the Notch signaling pathway.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

I make use of both, my clinical and research expertise in teaching. I teach Pathology and Internal Medicine residents and students clinical aspects of Hematology/Hematopathology. As well I give resident (Hematology/ Hematopathology, Oncology) seminars on tumor angiogenesis.

I teach graduate student courses using my expertise derived from my research interests in endothelial biology, apoptosis, angiogenesis and tumor biology, and stem cell differentiation. Currently much of my teaching time is spent on grad students, undergrads and high school students who are rotate through my laboratory.

Krajden, Mel

Portrait photo of Mel  Krajden

Krajden, Mel

BSc, MD (McG.), FRCPC

Academic Rank(s): Professor, Pathology and Laboratory Medicine, UBC | Medical Director, Public Health Serology, Provinical Health Services Laboratories | Director, BC Hepatitis Services, BC Centre for Disease Control, Laboratory Services | Associate Director, Laboratory Services | Head of Virology Section, BC Centre for Disease Control, Laboratory Services

Research and Scholarly Interests: Cancer, Infectious Diseases and Immunology Microbiology

Clinical Interests:

Short Bio
OpenClose

Dr. Mel Krajden, a Professor, is the Director of Hepatitis Services at BCCDC and Associate Director of the BCCDC Public Health Microbiology and Reference Laboratories. He oversees the research on the impact of hepatitis C virus on our society which has been recognized for the innovative advances of delivery of care to hepatitis patients outside large urban setting. His research focus is on the use of molecular markers to monitor anti-viral efficacy in vivo and of molecular techniques to track microbial infections for epidemiological purposes. He has particular expertise in quantitative nucleic acid testing of hepatitis B and C viruses and inter-assay evaluation. Recently he has undertaken research in human papillomaviruses including their detection in specific populations, their seroepidemiology and seroconversion after vaccination.

 

Academic
OpenClose

Academic Background

  • BSc, McGill University, Microbiology & Immunology. 1976
  • MD, McGill University. 1980
  • Royal College of Physicians and Surgeons FRCP(C) in Medical Microbiology. Dec 1987
  • Royal College of Physicians and Surgeons, Certificate of competency in Infectious Diseases. Dec 1986
  • Royal College of Physicians and Surgeons in Internal medicine FRCPC. Jun 1984

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Infectious Diseases
  • Cancer
  • Health Services Research
  • Biodata
    I am currently the Director of BC Hepatitis Services; Associate Director of Laboratory Services at the British Columbia Centre for Disease Control (BCCDC), Medical Director Public Health Serology, and Program Head of Virology. I am also a Professor of Pathology and Laboratory Medicine at the UBC. After earning my BSc and MD (1973-80) at McGill University I undertook Internal Medicine training at McGill University (1980-83). Thereafter I did a fellowship in Infectious Diseases at Stanford University (1983-86) and completed my Medical Microbiology residency at the University of Toronto (1986-87). Between 1991 and 1998 I was Section Head of Virology and Serology and an Infectious Diseases consultant at The Toronto Hospital (The University Health Network). In September 1998, I moved from Toronto to my position at the BC Centre for Disease Control (BCCDC) and the University of British Columbia. I am also an adjunct scientist with the Canadian Blood Services and member of the the Canadian Blood Services Scientific and Research Advisory Committee.
    My recent clinical research involves integration of hepatitis prevention and care services. My laboratory research involves in the application of molecular techniques to: diagnose viruses; assess correlates between infection and clinical disease; use molecular techniques to monitor antiviral efficacy; and track microbial infections for epidemiological purposes. I also have extensive clinical trials expertise and serve as a laboratory cooridinator for a number of national industry sponsored clinical trials.
    In 1999, together with Marlene Wong, of the Vancouver/Richmond Health Board I developed and submitted a proposal to the Province of British Columbia outlining an integrated hepatitis prevention and care management program. This program was base funded at approximately $5M per year on December 5, 2000, of which $1.3 M per year is allocated for coordination of hepatitis prevention and care management services in British Columbia.
    As a result, since 2001, I have been the Director of the Division of Hepatitis Services at the BCCDC. This division integrates diagnostic virology services within a comprehensive framework of consumer and professional education and funds five regional integrated hepatitis prevention and care demonstration projects within each of BC’s Health Authorities. Working with community partners these demonstration projects facilitate refinement and testing of new approaches for providing comprehensive services to hepatitis patients. Program activities include, health professional education, creating linkages between healthcare providers, enhancing nursing capacity and surveillance tools to define incident and prevalent hepatitis infections. This program which also supports guideline and policy development drives innovative system change.
    Hepatitis prevention and care is fundamentaly a model for an important paradox that Canada faces within its healthcare system. Hepatitis, like many other illnesses, is faced with the mixed blessing of rapidly evolving effective drug therapies that can improve outcomes and potentially cure infection for some. However the high cost (personal and financial) and complexity of these treatments requires careful utilization management to maintain a sustainable healthcare system. Equally important is the fact optimal outcomes result from both treatment and effective prevention. Prevention encompasses vaccination for hepatitis A and B, enhanced surveillance and targeted education including harm reduction interventions for hepatitis C. The specific needs of vulnerable populations, whose voice is often limited, cannot be ignored if mitigation of health disparities and control of communicable diseases is desired.
    Our model demonstrates that 80% to 90% of care and care for hepatitis C patients can be provided through non-physician allied healthcare professionals. However, funding for physicians and allied healthcare professionals follows silo’ed acute care or prevention based organizational structures which limit the necessary flexibility to support comprehensive service models. To address these needs, our hepatitis program has implemented a real-time link between PharmaCare and laboratories to provide cost-effective drug monitoring for hepatitis, saving approximately $700,000 per year in BC. With CIHR funding, we have been developing a prototypical mathematical model based on the natural history of HCV to estimate the current and future burden of disease in British Columbia. Our data support the need for thematic research across health promotion, prevention, care and treatment and must embrace consumers, providers and policymakers to stimulate greater collaboration between physicians and allied health service providers. The Hepatitis Program was recently showcased by the Provincial Health Services Authority as one of the best clinical research programs at the BC Centre for Disease Control.
    Other activities include a partnership with the Canadian Blood Services Vancouver/Yukon, the Provincial Blood Coordinating Office and the BC Centre for Disease Control, I have been instrumental in initiating an Anonymized Data Linkage Project: Application of Privacy Enhancing Technologies to Enhance Public Health and Blood Safety. This pilot project focuses on developing the policies and procedures that would permit real-time electronic sharing of non-nominal surveillance data between different agencies (public health, blood product recipients and CBS) to enhance blood safety.
    In addition, as the past Chair of the Joint Advisory Committee of the Health Canada/CIHR Hepatitis C Initiative I have played a key role in developing a national vision for an integrated health promotion, prevention, care and treatment hepatitis C research framework. All of these activities have occurred while making scholarly contributions to the field of diagnostic virology.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Krystal, Gerald

Krystal, Gerald

BSc, MSc, PhD (McGill)

Academic Rank(s): Professor, Distinguished Scientist, Pathology and Laboratory Medicine, UBC

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Endocrinology, Metabolism & Nutrition

Clinical Interests:

Short Bio
OpenClose

Krystal Lab

Our lab is interested in both the effects of various diets on cancer (CA) incidence and in determining who is at risk of developing CA so we can prevent it by adopting life style changes. In regard to the first goal, since tumour cells are more dependent on blood glucose than normal cells for their growth, we have been testing low carbohydrate (CHO) diets on mice and found they reduce the incidence, growth rate and metastasis of primary tumours. Related to this, we have been studying ways to alter the properties of the immune cells within tumours to enhance their ability to kill the CA cells. Because many tumours secrete factors that subvert the ability of tumour-infiltrating immune cells to kill CA cells, we have been examining the effects of different immune modulating agents and found that low levels of non-steroidal anti-inflammatory drugs like Celebrex, in conjunction with our low CHO diets, dramatically reduce the growth rate of tumours.

In regard to the second goal, there is growing evidence that low levels of chronic inflammation (CI), i.e., below those manifesting in obvious disease, coupled with a poor immune response to viral infections increase the incidence of many human CAs. Thus the identification of individuals with low but detectable levels of CI and a poor anti-viral response would be of great value in indentifying high-risk people. As well, recent research has shown that what we eat determines the type of bacteria that reside in our gut (i.e., our gut microbiome) and these bacteria likely play an important role in determining our levels of CI. Lastly, macrophages (MФs), which are key immune cells in all our tissues, vary from person to person in their properties, from being skewed to very pro-inflammatory (M1 or killer MФs) in some people to very anti-inflammatory (M2 or healer MФs) in others, with most people being somewhere in between. Since MФs secrete many immune modulators, where on this spectrum a person’s MФs exist profoundly influences his/her level of CI and ability to fight off infections.

To explore all these areas further we have devised a series of simple tests in which very small amounts of whole human blood are both tested for markers of CI and incubated for 7 hours in the presence and absence of live bacteria and viruses to assess an individual’s immune response. As well, small fecal samples are analyzed to determine the bacterial makeup of our gut in order to relate the presence of specific bacteria with levels of CI to gain insight into which bacteria may be beneficial and which may be harmful. Ultimately, we hope to identify specific immune markers that can be used to predict an individual’s susceptibility to developing CA.

We are also interested in searching for nature-derived compounds that may be used to modulate our immune responses to prevent or treat CA and, lastly, since we have recently elucidated the factors in mouse blood that dramatically influence the skewing of MФs we would now like to determine if the same factors play a role in skewing human MФs. Identifying them would enable treatments to reduce CI and fight off infections and CA cells more effectively.

Credentials
  • Professor, Pathology & Laboratory Medicine, University of British Columbia (UBC)
  • Member, Experimental Medicine, University of British Columbia (UBC)
  • Member, Genetics, University of British Columbia (UBC)

 

Academic
OpenClose

Academic Background

  • PhD, Biochemistry Dept. McGill University, Protein Chemistry. 1975
  • MSc, Cancer Unit, McGill University, Enzymology. 1971
  • BSc, McGill University, Biological Sciences. 1966

Awards and Recognition

Publications

PUBMED, Gerald Krystal

Selected Publications

Research
OpenClose

Research Interest

  • Blood research
  • Immunology
  • Inflammation
  • Effect of diet on cancer

Our lab is interested in both the effects of various diets on cancer (CA) incidence and in determining who is at risk of developing CA so we can prevent it by adopting life style changes. In regard to the first goal, since tumour cells are more dependent on blood glucose than normal cells for their growth, we have been testing low carbohydrate (CHO) diets on mice and found they reduce the incidence, growth rate and metastasis of primary tumours. Related to this, we have been studying ways to alter the properties of the immune cells within tumours to enhance their ability to kill the CA cells. Because many tumours secrete factors that subvert the ability of tumour-infiltrating immune cells to kill CA cells, we have been examining the effects of different immune modulating agents and found that low levels of non-steroidal anti-inflammatory drugs like Celebrex, in conjunction with our low CHO diets, dramatically reduce the growth rate of tumours.

In regard to the second goal, there is growing evidence that low levels of chronic inflammation (CI), i.e., below those manifesting in obvious disease, coupled with a poor immune response to viral infections increase the incidence of many human CAs. Thus the identification of individuals with low but detectable levels of CI and a poor anti-viral response would be of great value in indentifying high-risk people. As well, recent research has shown that what we eat determines the type of bacteria that reside in our gut (i.e., our gut microbiome) and these bacteria likely play an important role in determining our levels of CI. Lastly, macrophages (MФs), which are key immune cells in all our tissues, vary from person to person in their properties, from being skewed to very pro-inflammatory (M1 or killer MФs) in some people to very anti-inflammatory (M2 or healer MФs) in others, with most people being somewhere in between. Since MФs secrete many immune modulators, where on this spectrum a person’s MФs exist profoundly influences his/her level of CI and ability to fight off infections.

To explore all these areas further we have devised a series of simple tests in which very small amounts of whole human blood are both tested for markers of CI and incubated for 7 hours in the presence and absence of live bacteria and viruses to assess an individual’s immune response. As well, small fecal samples are analyzed to determine the bacterial makeup of our gut in order to relate the presence of specific bacteria with levels of CI to gain insight into which bacteria may be beneficial and which may be harmful. Ultimately, we hope to identify specific immune markers that can be used to predict an individual’s susceptibility to developing CA.

We are also interested in searching for nature-derived compounds that may be used to modulate our immune responses to prevent or treat CA and, lastly, since we have recently elucidated the factors in mouse blood that dramatically influence the skewing of MФs we would now like to determine if the same factors play a role in skewing human MФs. Identifying them would enable treatments to reduce CI and fight off infections and CA cells more effectively.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Lam, Wan

Lam, Wan

BSc, MSc, PhD, (Dalhousie Univ), MRC

Academic Rank(s): Professor, Pathology and Laboratory Medicine, UBC | Director, Interdisciplinary Oncology Program, Faculty of Medicine, UBC

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Cardiovascular and Pulmonary, Clinical Applied Research, Genetics genomics proteomics and related approaches, Molecular Pathology and Cell Biology, Genome biology, Epigenetics, Molecular Systems Biology

Clinical Interests:

Short Bio
OpenClose

Wan Lam Lab

Dr. Wan Lam is a Professor of Pathology and Laboratory Medicine at the University of British Columbia. He is Deputy Head and a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. He received his PhD in Biochemistry at Dalhousie University with National Academy of Sciences member Dr. W. Ford Doolittle and trained as a post-doctoral fellow with Nobel Laureate Dr. Walter Gilbert at Harvard University. He received the William E. Rawls Prize from the Canadian Cancer Society for his work. Dr. Lam is internationally recognized for his work investigating the genetic and epigenetic basis of a wide variety of cancers, especially in lung cancer. He has produced nearly 300 peer-reviewed publications and holds patents on signatures for prognosis and therapy responsiveness in lung cancer. His lab has provided academic training for over 60 graduates and post-doctoral fellows to date, many of whom have since established themselves in leading clinical and health research positions.

Current Appointments

  • Professor, Department of Pathology and Laboratory Medicine, UBC
  • Director, Interdisciplinary Oncology Program, Faculty of Medicine, UBC

 

Academic
OpenClose

Academic Background

  • Postdoctoral Research Associate (Molecular and Cellular Biology) Harvard University. 1994-1998
  • MRC Postdoctoral Fellow (Cellular and Developmental Biology) Harvard University. 1991-1994
  • PhD (Biochemistry) Dalhousie University. 1991
  • BSc and MSc (Microbiology), University of Alberta. 1983, 1986

Awards and Recognition

Publications

Publications are listed at http://www.bccrc.ca/dept/ic/genetics/dr.-wan-lam-phd

Selected Publications

  • Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, Snijders A, Albertson DG, Pinkel D, Marra MA, Ling V, MacAulay, C, Lam WL (2004) A tiling resolution DNA microarray with complete coverage of the human genome. Nature Genetics 36: 299-303.
  • Weber M, Davies JJ, Wittig D, Haase M, Lam WL, Schübeler D (2005) Chromosome-wide and promoter-specific analyses reveal sites of differential DNA methylation in normal and transformed human cells. Nature Genetics 37: 853-62.
  • Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS (2008) Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc. Natl. Acad. Sci. U.S.A. 105: 10155-60.
  • Starczynowski D, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells R, Lam W, Humphries K, Karsan A (2010) Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine 16: 49-58.
  • Vucic, EA, Thu KL, Robison K, Rybaczyk L, Chari R, Alvarez CE, Lam WL (2012) Translating cancer omics to outcomes. Genome Research 22:188-95.
  • Pikor LA, Lockwood WW, Thu KL, Vucic EA, Chari R, Gazdar AF, Lam S, Lam WL (2013) YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. Cancer Research 73:7301-12.
  • Martinez VD, Vucic EA, Thu KL, Hubaux R, Enfield KSS, Pikor LA, Becker-Santos DD, Brown CJ, Lam S, Lam WL (2015) Unique somatic and malignant expression patterns implicate PIWI-interacting RNAs in cancer-type specific biology. Scientific Reports 5:10423, 1-17.
  • Conway EM, Pikor LA, Kung SHY, Hamilton M, Lam S, Lam WL, Bennewith KL (2016) Macrophages, inflammation and lung cancer. American Journal of Respiratory and Critical Care Medicine 193:116-30.
  • Becker-Santos DD, Thu KL, English JC, Pikor LA, Martinez VD, Zhang M, Vucic EA, Luk MT, Carraro A, Korbelik J, Piga D, Lhomme NM, Tsay MJ, Yee J, MacAulay CE, Lam S, Lockwood WW, Robinson WP, Jurisica I, Lam WL (2016) Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma. Journal of Pathology 240:161-72.
  • Minatel BC, Sage AP, Anderson C, Hubaux R, Marshall EA, Lam WL, Martinez VD (2017) Environmental arsenic exposure: genetic and epigenetic contributions to carcinogenesis. Environment International 112:183-197.
  • Ng KW, Marshall EA, Bell JC, Lam WL (2018) The emerging tumorigenic capacity of cGAS-STING. Trends in Immunology 39:44-54.
Research
OpenClose

Research Interest

  • Cancer progression
  • Genome biology
  • Epigenetics
  • Molecular Systems Biology
  • Lung Cancer
  • Technology Development
  • Dr. Lam’s primary research interest is in understanding the events leading to cancer progression. Early detection and treatment is key to a favorable prognosis in cancer. His laboratory at the British Columbia Cancer Research Centre (http://www.bccrc.ca/dept/ic/genetics) has developed novel whole genome approaches for tracking genetic, epigenetic and gene expression changes in order to identify genes and pathways critical to cancer progression and signatures for treatment response.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Mackenzie, Ian

Mackenzie, Ian

MD, LMCC, FRCPC

Academic Rank(s): Professor, Department of Pathology & Laboratory Medicine, Faculty of Medicine, UBC | Consultant Neuropathologist at Vancouver Acute and BC Cancer Agency

Affiliation(s): VGH & Djavad Mowafaghian Centre for Brain Health

Research and Scholarly Interests: Dementia, frontotemporal dementia, amyotrophic lateral sclerosis, neurodegenerative disease, proteinopathy, molecular genetics

Clinical Interests: neuropathology, focusing on the use of brain tissue in various clinical contexts

Short Bio
OpenClose

Dr. Ian MacKenzie is a Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia (UBC). He also serves as a Consultant Neuropathologist at Vancouver Acute and BC Cancer Agency and is the Head of Neuropathology at Vancouver General Hospital. His academic and professional journey includes significant expertise in neuropathology and the use of brain tissue banks for patients with neurological disorders. Dr. MacKenzie’s research focuses on the molecular genetics of neurodegenerative diseases, particularly dementias, and he is involved in various neuropathology journals and international societies​ (Pathology)​​ (centreforbrainhealth)​​ (Pathology)​.

Academic
OpenClose

Academic Background

  • Certificate of the Royal College of Physicians and Surgeons of Canada (FRCPC) Neuropathology. 1989
  • MD, University of Western Ontario, London, Medicine. 1984
  • University of Western Ontario, London, Chemistry (Honours). 1980

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

Dr. Ian Mackenzie, a neuropathologist, has extensive expertise in using brain tissue banks in the care of patients with neurological disorders. His research program centres on neuropathology and the molecular genetics of neurodegenerative disease, particularly dementias. He leads the program on FTD that has resulted in the discovery of several gene mutations that cause this disease. Specifically, Drs. Mackenzie and Hsiung, along with collaborators from the Mayo Clinic and the University of California, San Francisco, are investigating a common genetic mutation underlying amyotrophic lateral sclerosis and a form of dementia helps to explain why many patients with those diseases get symptoms of the other. This finding was significant because the implications of finding the common genetic mutation to two diseases may lead to a treatment that could be used for both.

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dr. Luo is actively involved in graduate-level teaching.

McManus, Bruce

McManus, Bruce

PhD, MD, FRSC, FCAHS

Academic Rank(s): Professor Emeritus, Pathology and Laboratory Medicine, UBC | Centre for Heart Lung Innovation (HLI), CEO, Prevention of Organ Failure Centre of Excellence (PROOF Centre)

Affiliation(s): St. Paul’s Hospital / HLI

Research and Scholarly Interests: Cardiovascular and Pulmonary, Genetics genomics proteomics and related approaches, Infectious Diseases and Immunology Microbiology, Professional Contributions

Clinical Interests:

Short Bio
OpenClose

Bruce McManus is Professor Emeritus, Department of Pathology and Laboratory Medicine, the University of British Columbia. He serves as CEO, Centre of Excellence for Prevention of Organ Failure (PROOF Centre) and Co-Director, Institute for Heart + Lung Health.

Dr. McManus received BA and MD degrees (University of Saskatchewan), an MSc (Pennsylvania State University), and the PhD (University of Toledo). He pursued post-doctoral fellowships at the University of California – Santa Barbara (Environmental Physiology) and at the National Heart, Lung, and Blood Institute, Bethesda, MD (Cardiovascular & Pulmonary Pathology), and residency training at the Peter Bent Brigham Hospital – Harvard University (Internal Medicine and Pathology). Dr. McManus joined the Faculty of Medicine, the University of British Columbia, as Department Head of Pathology and Laboratory Medicine in 1993, serving until 2000. He then served as inaugural Scientific Director of the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research from 2000 to 2006, and as Director of the James Hogg Research Centre from 2006-2012.

Dr. McManus’ investigative passion relates to mechanisms, consequences, detection and prevention of injury and aberrant repair in inflammatory diseases of the heart and blood vessels. He currently leads a diverse team of scientists devoted to trans-omic biosignature development. His life’s scholarship is reflected in nearly 400 original peer-reviewed publications, >50 chapters and several books. Dr. McManus is co-founder of the Personalized Medicine Initiative of British Columbia, as well as numerous life sciences and technology start-ups. He champions the power of consortium in solving pressing health science issues.

Dr. McManus has been widely appreciated for his research, mentoring and leadership contributions to the health sciences. In 2015, he received the University of British Columbia Faculty of Medicine Distinguished Achievement Award for Senior Faculty, the Canadian Blood Services Lifetime Achievement Award, the Howard Morgan Award from the International Academy of Cardiovascular Sciences and the Jacob Biely Faculty Research Prize from University of British Columbia.

 

Academic
OpenClose

Academic Background

  • University of Saskatchewan MD Medicine. 1973-1977
  • University of Toledo PhD Exercise Physiology and Biochemistry. 1969-1972
  • Pennsylvania State University MSc Exercise Physiology. 1967-1969
  • University of Saskatchewan BA Biology and Physical Education. 1963-1967

Professional Qualifications

  • Fellowship, Royal College of Physicians and Surgeons (Pathology). Sept 1993
  • Medical Licensure: British Columbia. Aug 1993
  • Medical Licensure: Nebraska. Jun 1982
  • American Board of Pathology, Anatomic Pathology. Nov 11, 1980
  • Medical Licensure: Maryland. Oct 1980
  • Medical Licensure: Massachusetts. Aug 1978
  • National Board of Medical Examiners, Parts I and II. 1978
  • Licensure Medical Council of Canada. 1977

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Cardiovascular & Pulmonary
  • Genomic Science
  • Immunology
  • Molecular Pathology
  • Current research activities center on injury and repair processes in inflammatory diseases of the heart and blood vessels:
    Inflammatory and viral basis of myocardial injury
  • Detection of viral infection
  • The role of immunomodulatory therapy in prevention of myocardial injury in human and animal model myocarditis and in allograft rejection
  • The pathobiology of heart allograft vasculopathy
  • Genomic, proteomic and metabolomic biomarkers of allograft rejection and of atherosclerosis
  • The progression to cardiomyopathic states
  • The genetic determinants and pathobiology of heart valve disease

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Noble, Michael

Noble, Michael

MD, FRCPC

Academic Rank(s): Professor Emeritus, Pathology and Laboratory Medicine, UBC | Medical Microbiologist, LifeLabs Medical Laboratory Services (formerly) | Medical Microbiologist, Vancouver Coastal Health (formerly)

Affiliation(s): UBC Hospital

Research and Scholarly Interests: Molecular Pathology and Cell Biology, Professional Contributions

Clinical Interests:

Short Bio
OpenClose

Dr. Noble career began in 1978 as a medical microbiologist, but overtime issues associated with laboratory quality improvement became central to his work focus. Within the Department of Pathology and Laboratory Medicine, he developed the Clinical Microbiology Proficiency Testing (CMPT) program in 1983, from a program designed to provide quality assistance for lower mainland hospitals to an international structure with interests both in clinical microbiology as well as drinking and recreational water safety. Through CMPT he created the first international training program for External Quality Assessment, teaching laboratorians essential sample production procedures. In 2003 as a result of his work with International Organization for Standardization he created the UBC Program Office for Laboratory Quality Management anessed the UBC Certificate Course in Laboratory Quality Management to help laboratorians around the world in Quality Management and Quality Improvement. . Through these two programs, he has remained actively engaged in laboratory quality education, research, and outreach on both national and international levels.

In 2013, he was appointed as the co-chair (faculty) for the Department of Pathology and Laboratory Medicine UBC Site Safety Committee (2013-2018).

Outside of the Department he works regularly with the International Organization for Standardization (ISO), Standards Council of Canada (SCC), Canadian Standards Association (CSA), Clinical and Laboratory Standards Institute (CLSI) , University of Washington International Training and Education Center for Health (ITECH), US Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and the European Organisation for Quality Assurance in Laboratory Medicine. (EQALM)

Dr. Noble maintains an active blog Making Medical Lab Quality Relevant (www.medicallaboraotryquality.com).

 

Expertise:

  • Laboratory Quality Management (medical qualitologist)
  • Medical Microbiology
  • Laboratory Safety
  • External Quality Assessment based on clinical sample simulation
  • Teaching and training

 

Academic
OpenClose

Academic Background

  • Certification in Specialty of Medical Microbiology, FRCP(C), 1978
  • Certification in Specialty of Internal Medicine, FRCP(C), 1977
  • MD, University of Western Ontario, Zoology. 1972
  • BA, University of Western Ontario, Zoology.  1968

Awards and Recognition

Publications

Selected Publications

  • Felicity Gopolang, Fales Zulu-Mwamba, Davy Nsama, Annika Kruuner, Dailes Nsofwa, Ishmael Kasvosve, Royce Gomo, Tiny Motlhabane, Bhavna Chohan, Olusegun Soge, Daniel Osterhage, Nancy Campbell, Michael Noble, Ann Downer, Jean-Frederic Flandin, Anya Nartker, Catherine Koehn, Linda K. Nonde, Aaron Shibemba, Clement B. Ndongmo, Martin Steinau, Lucy A. Perrone. Improving laboratory quality and capacity through leadership and management training: Lessons from Zambia 2016–2018 African Journal of Laboratory Medicine | Vol 10, No 1.
  • Noble MA, Rennie R Combined international external quality assessment results of medical laboratory performance and reporting of samples with known antimicrobial resistance. Diagnosis (Berl). 2018 Jun 15. pii: /j/dx.ahead-of-print/dx-2018-0020/dx-2018-0020.xml. doi: 10.1515/dx-2018-0020. [Epub ahead of print]
  • Noble MA, Restelli V, Taylor A, Cochrane D, 2018. Laboratory error reporting rates can change significantly with year-over-year examination. Diagnosis (Berl). 2018 Mar 28;5(1):15-19. doi: 10.1515/dx-2017-0043.
  • Veronica Restelli, Annemarie Taylor, Douglas Cochrane and Michael A. Noble 2017. * Medical laboratory associated errors: the 33-month experience of an on-line volunteer Canadian province wide error reporting system Diagnosis (De Gruyter) May 8, 2017
  • Michael A Noble. 2015. Clinical Microbiology Proficiency Testing program: Thirty-three years of evolution and progress. 5th International Proficiency Testing Conference (PTConf): Proceedings.
  • Jane Lea, Anne Elizabeth Conlin, Inna Sekirov, Veronica Restelli, Komathi G Ayakar, LeeAnn Turnbull, Patrick Doyle, Michael Noble, Robert Rennie, William E Schreiber, and Brian D Westerberg, In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media. J Otolaryngol Head Neck Surg. 2014; 43(1): 20.
  • Michael A Noble, Robert Martin. 2014. Editorial – Making Great Strides in Medical Laboratory Quality. African Journal for Laboratory Medicine. Accepted for Publication.
  • Noble MA. 2013. Making progress in implementing quality in Canadian medical laboratories. Clin Biochem. 2013 Sept;46(13-14).
  • Vernelen K, Noble MA, Sourdeau L, Libeer J-C. External quality assessment in microbiology: a comparison between the results from Belgian and Canadian laboratories with regard to their ability to identify S. pyogenes. Accreditation and Quality Assurance. 2008; 13(9) 501-504.
  • Noble MA. Does external evaluation of laboratories improve patient safety? Clin Chem Lab Med. 2007;45(6):753-5. Review.
  • Julie Gayken, Michael Noble, Julie Taylor, Paul Epner, Charles Fenstermaker, Shahram Shahangian, David Bruns, Nancy Elder, Barbara Goldsmith, Jennifer McGeary, Barbara Mitchell, Margaret Piper, David Sundwall . 2005 IQLM and CLMA take a snapshot of America’s hospital laboratory quality management. Clinical leadership & management review: the journal of CLMA 02/2005; 19(5):E2.
  • Noble MA. Medical laboratories can be unsafe places. ISO Focus. 2004; 1;1:40-41.
  • Yassi A, Noble MA, Daly P, Bryce E. Severe acute respiratory syndrome: guidelines were drawn up collaboratively to protect healthcare workers in British Columbia. BMJ. 2003; 21; 326(7403):1394-5.
  • Boone DJ, Noble MA. editorial: Global Odyssey 2002: International conference on proficiency testing for medical laboratories. Accred Qual Assur 7. 2002; 8-9, 317-319.
Research
OpenClose

Research Interest

  • Development and Design for clinical sample simulations
  • Costs of Poor Quality associated with Laboratory Error
  • Impact of Organizational Culture on Laboratory Error

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

  • Module 1 Standards and Quality Management
  • Module 3 Costs of Poor Quality and Quality Partnerships
  • Module 4 Modern Tools for Culture of Quality

International Training for National EQA

  • Abuja Nigeria October 2019
  • Addis Ababa Ethiopia May 2020
  • Thies Senegal September 2021
  • Conakry Guinea February 2022

Owen, David

Portrait photo of David Owen

Owen, David

MB (Wales), FR

Academic Rank(s): Professor Emeritus, Pathology and Laboratory Medicine, UBC | Consultant Pathologist, Vancouver General Hospital, Division of Anatomical Pathology | Consultant, British Columbia Cancer Agency, Department of Pathology

Affiliation(s): VGH/VCHRI

Research and Scholarly Interests: Gastrointestinal systems, Digestive System, Hepatic Pathology

Clinical Interests:

Short Bio
OpenClose

Dr. Owen is from North Wales. He received his medical degree at the University of Wales and his training in Pathology at St. Thomas’ Hospital Medical School in London, England. He immigrated to Canada in 1976 and spent four years at the University of Manitoba in Winnipeg before moving to Vancouver in 1980. Currently he is Professor of Pathology in the Department of Pathology and Laboratory Medicine at the University of British Columbia and Consultant Pathologist at Vancouver General Hospital. He has authored or co-authored over 100 articles in the medical literature and is co-author of a textbook of pancreatic pathology.

Dr. Owen’s major interest is in the morphologic aspects of gastrointestinal and pancreatic disease including the influence of histopathologic appearances on the prognosis of malignant neoplasms.

 

Academic
OpenClose

Academic Background

  • MB, BCh, University of Wales, Medicine and Surgery. 1967

Professional Qualifications

  • Royal College of Pathologists of Great Britain: Membership 1974 (by examination); Promoted to Fellow, (FRCPath). 1987
  • Province and British Columbia: Licensed Physician and Certified Specialist in Anatomical pathology. 1980 – present
  • Royal College of Physicians and Surgeons of Canada: Fellow and Certified Specialist in Anatomical Pathology, (by examination)  (FRCPC). 1977
  • Medical Council of Canada: Licentiate. 1977
  • Province of Manitoba: Licensed Physician, 1976 and Certified Specialist in Anatomical Pathology. 1977

Awards and Recognition

Publications

Selected Publications

  • Geramizadeh B, Marzban M, Owen DA. Malignant colorectal polyps; Pathological considerations (A review). Iran J Pathol 2017:12;1-8.
  • Owen DR, Owen DA. Celiac disease and other causes of duodenitis. Arch Pathol Lab Med 2017 (in press).
  • Alshafi M, Owen D, Donnellan F. A rare cause of a subepithelial periampullary duodenal lesion. Clin Gastroenterol Hepatol 2017 (in press).
  • Geramizadeh B, Owen D. Handling and pathology reporting of gastrointestinal mucosal resections. Middle East J Dig Dis 2017;9:5-11.
  • Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS. The differential effects of metronomic gemcytabine and angiogenic treatment in patient-derived xenografts of pancreatic cancer. Treatment effects on metabolism, vascular function, cell proliferation and tumor growth. Angiogenesis 2016;19:229-244.
  • Leo JM, Kalloger SE, Peixoto RD, Gale NS, Webber DL, Owen DA, Renouf D, Schaeffer DF. Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subtypes. J Clin Pathol 2016;69:431-439.
  • O’Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsh R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015;39:472-478.
  • Verdun TP, Owen DA. Primary peritoneal ependymoma. Pathol Res Pract 2015;211:268-2
  • Klass D, Owen D, Buczkowski A, Chung SW, Scudamore CH, Weiss AA, Yoshida EM, Ford JE, Ho S, Liu DM. The effect of Doxirubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: A dose escalation study. Anticancer Res 2014;34;3597-3606.
  • Klass D, Owen D, Buczkowski A, Chung SW, Scudamore CH, Weiss AA, Yoshida EM, Ford JE, Ho S, Liu DM. The effect of Doxirubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: A dose escalation study. Anticancer Res 2014;34;3597-3606.
  • Verdun TP, Owen DA. Primary peritoneal ependymoma. Pathol Res Pract in press. 2014
  • Griffith M, Mwenifumbo JC, Cheung PY, Paul TJ, Tang MJ, Chittaranjan S, Mori RD, Asano JK, Ally AA, Miao L, Lee A, Chan SY, Taylor G, Severson T, Hou YC, Griffith OL, Cheng GS, Novik K, Moore R, Luk M, Owen D, Brown CJ, Morin GB, Gill S, Tai IT, Marra MA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-FU resistance in colorectal cancer. Pharmocogenetics J 2013;13:158-158.
  • Degroote D, Knippenberg L, Borght SV, Spaepen M, Matthis G, Schaeffer DF, Owen DA, Libbrecht L, Lambein K, de Hertogh G, Toussevn T, Sagaert X. Analysis of microsatellite instability in gastric mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma 2013;54:812-818.
  • Wong JC, Hasan MR, Rahman M, Yu JC, Chan SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D, Tai IT. Nucleophosphmin 1, upregulated in cancers of the colon, inhibits a p53 mediated cellular senescence. Int J Cancer 2013;133:1567-1577.
  • Short MA, Tai IT, Owen D, Zeng H. Using high-frequency Raman spectra for colonic neoplasia detection. Opt Express 2013;25:5025-5034.
  • Garung A, Owen DA. Giant fibrovascular polyp of the esophagus. Pathol Case Rev 2013;18:67-69.
  • Assi K, Bergstrom K, Vallence B, Owen D, Salh B. Requirement of intergrin-linked kinase for facilitation od Citrobacter rodentium-induced colitis. BMC Gastroenterology 2013;13:137.
  • Yap WW, Kirke R, Yoshida EM, Owen D, Harris AC. Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study. Ann Hepatol 2013;12:608-615
Research
OpenClose

Research Interest

  • Digestive System
  • Gastrointestinal and Hepatic Pathology

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Schreiber, William

Portrait photo of William  E. Schreiber

Schreiber, William

MD, DABP

Academic Rank(s): Professor Emeritus, Pathology and Laboratory Medicine, UBC

Affiliation(s): LifeLabs

Research and Scholarly Interests:

Clinical Interests:

Short Bio
OpenClose

Dr. Schreiber is the Clinical Director of Chemistry at LifeLabs. In this role, he provides medical oversight for all chemistry testing in British Columbia. Prior to joining LifeLabs, he worked in the Division of Clinical Chemistry at Vancouver General Hospital. He also served as medical director of the Provincial Toxicology Center, which provides both forensic and clinical toxicology services for the entire province.

Since joining the faculty at UBC, he has committed a large part of his career to the education of medical students, residents and colleagues. He directed the medical biochemistry residency program for 10 years and served as associate dean for undergraduate education at UBC from 1999-2002. He has received a number of teaching awards from students and peers, as well as recognition from professional organizations for contributions to continuing medical education. His recently published book, An Introduction to Testing for Drugs of Abuse (Wiley-Blackwell), is available at https://www.wiley.com/en-ca/An+Introduction+to+Testing+for+Drugs+of+Abuse-p-9781119794059.

In 2016-2017, Dr. Schreiber served as president of the American Society for Clinical Pathology (ASCP), the largest pathology organization in North America.

 

Academic
OpenClose

Academic Background

  • BA, Oberlin College, 1975
  • MD, Baylor College of Medicine, 1979
  • Residency & Research Fellowship, University of Washington, 1979-1984
  • Diplomate, American Board of Pathology, 1985

Awards and Recognition

  • Medical Undergraduate Society Teaching Excellence Award – 1989, 1992, 1993, 1997
  • The University of British Columbia Teaching Prize – 1994
  • 3M Teaching Fellowship – 1996
  • Outstanding Speaker Award, American Association for Clinical Chemistry – 1996, 1997, 2009
  • Education Excellence Award, Canadian Society of Clinical Chemists – 1998
  • Honorary Alumnus Award, UBC Alumni Association, Medical Division – 1998
  • CCE Distinguished Service Award, American Society of Clinical Pathologists – 1999
  • Distinguished Service to CME/CPD Award, UBC Faculty of Medicine – 2009

Publications

PubMed

Selected Publications

Research
OpenClose

Research Interest

I have a longstanding interest in diseases of porphyrin metabolism and their diagnosis.  Our laboratory developed improved biochemical tests for porphyrins and their precursors in human samples.  We also applied the techniques of molecular biology to characterize mutations that cause acute intermittent porphyria and hereditary coproporphyria.

More recently, I have collaborated on projects in the fields of clinical and forensic toxicology.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Teaching students, residents and colleagues is an essential part of my work.  In addition to lectures and small group sessions at UBC, I continue to present educational sessions at national meetings.

An Introduction to Testing for Drugs of Abuse was published by Wiley-Blackwell in 2022.  This book provides practical guidance to pathologists, clinical laboratory scientists, technologists and other health care professionals on how to order and interpret drug tests accurately.  It is available at the following website:

https://www.wiley.com/en-ca/An+Introduction+to+Testing+for+Drugs+of+Abuse-p-9781119794059

Seow, Chun

Seow, Chun

BSc (Manitoba), PhD (Manitoba)

Academic Rank(s): Professor Emeritus, Department of Pathology & Laboratory Medicine, Faculty of Medicine, UBC

Affiliation(s): Centre for Heart Lung Innovation (HLI), St. Paul’s Hospital

Research and Scholarly Interests: Muscle mechanics, airway smooth muscle, smooth muscle biochemistry, lung mechanics, asthma, and mechanopharmacology

Clinical Interests: studying the basic mechanisms of muscle contraction and how airway smooth muscle dysfunction contributes to airway hyper-responsiveness in asthma

Short Bio
OpenClose

Dr. Seow received his BSc degree in Mechanical Engineering and PhD degree in Physiology from the University of Manitoba. He received his post-doctoral training in muscle mechanics at the University of Chicago. In 1996 he was recruited to UBC as a CIHR New Investigator (1996-2001) and CIHR/BC Lung Investigator (2001-2006). His research projects have been continuously funded by CIHR since 1996 without interruption. His research has also been supported by NSERC for the last 15 years. He is member of the American Physiological Society, the Biophysical Society, the American Society of Mechanical Engineers, and Fellow of the American Thoracic Society. He became Professor Emeritus on July 1, 2024.

Academic
OpenClose

Academic Background

  • Post Doctoral Training, University of Chicago, Muscle Biophysics. 1989-1992
  • PhD, University of Manitoba, Physiology. 1989
  • BSc, University of Manitoba, Mechanical Engineering. 1984

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

Dr. Seow’s current research program has two major foci, one on understanding the basic mechanism of contraction in smooth muscle, with an emphasis on airway smooth muscle function and dysfunction associated with asthma; the other one is on understanding isolated lung function in terms of lung mechanics and pharmacology.

For smooth muscle research the Seow lab employed 3 major approaches:

  • 1) Relating changes in cell mechanics to intracellular ultrastructural changes such as myosin and actin filament polymerization to determine the structure-function relationship.
  • 2) Relating changes in mechanical function to pharmacological interventions that perturb the network of signalling associated with smooth muscle activation and adaptation, in order to reveal drug targets for regulating smooth muscle contraction.
  • 3) Relating changes in mechanical properties to chemical interventions that alters protein expression and phosphorylation of enzymes and structural proteins, in order to understand the mechanism of contraction and its regulation.

A sophisticated ventilation chamber (plethysmograph) for isolated sheep and human lungs has been developed in the Seow lab recently to assess lung functional change (lung and airway resistance and elastance) in response to mechanical or pharmacological challenges. The setup allows positive or negative pressure ventilation at multiple tidal frequencies and volumes while the structural changes within the lung are recorded by a CT scanner. It also allows assessment of impact of changes in airway smooth muscle on the whole lung function and enables a“molecule-to-organ” type of approach.

  • Airway smooth muscle
  • Asthma
  • Respiratory System
  • Lung Mechanics
  • Muscle mechanics
  • Muscle biochemistry
  • Muscle ultrastructure

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Path 301, section of bioenergetics

Path 438, Course Coordinator

Path 521, Course Coordinator

Anat 527, Course Coordinator

Sorensen, Poul

Sorensen, Poul

BSc, MD (McGill Univ), PhD, FRCPC

Academic Rank(s): Professor, Pathology and Laboratory Medicine, UBC | Distinguished Scientist, Johal Chair in Childhood Cancer Research

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Molecular Pathology and Cell Biology, Professional Contributions

Clinical Interests:

Short Bio
OpenClose

Sorensen Lab

Dr. Poul Sorensen is a board certified anatomic pathologist, specializing in the molecular pathology of pediatric cancers. He undertook his undergraduate, medical, and PhD degrees at the University of British Columbia (UBC) and McGill University, Montreal. He completed postdoctoral training at the University of Minnesota, Minneapolis and Children’s Hospital Los Angeles, University of Southern California, after his Pathology training.  He then returned to Vancouver to start his own laboratory at Children’s and Women’s Hospital in Vancouver. Dr. Sorensen holds the Asa and Kashmir Johal Endowed Chair in Childhood Cancer Research, and he is Professor of Pathology and Laboratory Medicine at UBC. Dr. Sorensen’s research laboratory is located in the Department of Molecular Oncology at the BC Cancer Research Centre, where he is a distinguished scientist. His research focuses on targeting aberrant signaling pathways that are activated in childhood cancers and breast carcinoma.

Dr. Sorensen’s laboratory uses a combination of genetic and biochemical approaches to identify proteins that are specifically altered in human tumours. His laboratory has discovered many novel genetic alterations in childhood cancer and breast tumours, and these discoveries have been translated into new diagnostic tests for specific tumours, and have advanced our understanding of how the involved proteins transmit signals that cause cells to become cancerous. Such information then allows for the rapid implementation of strategies to target these proteins therapeutically. Dr. Sorensen is also the Chair of the Translational Research Committee of the Children’s Oncology Group (COG), the largest pediatric oncology clinical trials network in the world.

Affiliations

University of British Columbia, Pathology and Laboratory Medicine
University of British Columbia, Pediatrics Department
University of British Columbia, Department of Urologic Sciences

Credentials

Senior Research Scientist (Honorary), Vancouver Prostate Cancer
Professor, University of British Columbia
Asa and Kashmir Johal Endowed Chair in Childhood Cancer Research, University of British Columbia, Department of Pediatrics

Publications (link to Pubmed)

BC Cancer Foundation blog

psor [at] interchange [dot] ubc [dot] ca

Read news about the Sorensen Lab here.

 

Academic
OpenClose

Academic Background

  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) – Anatomical Pathology. 1991
  • PhD, University of British Columbia, Canada. 1990
  • MD, University of British Columbia, Canada. 1984
  • BSc (Honours Chemistry /Biochemistry), McGill University, Montreal, Canada. 1980

Awards and Recognition

Publications

Full list of publications may be found here

Selected Publications

Research
OpenClose

Research Interest

Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers

High-risk pediatric cancers remain the leading cause of mortality in childhood, and current standard approaches to treat pediatric cancers frequently induce unacceptable life-long morbidity. This multi-center collaborative effort focuses on identifying and understanding the fundamental mechanisms leading to high-risk childhood cancers, including how these malignancies evolve to evade the immune system and resist modern therapies. These discoveries will subsequently be translated into novel new immunotherapeutic strategies for children, adolescents and young adults with cancer, which are predicted to improve cure rates while diminishing the long-term toxicity experienced by survivors.

Clinical Service

Current Projects In My Lab Include

Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers

High-risk pediatric cancers remain the leading cause of mortality in childhood, and current standard approaches to treat pediatric cancers frequently induce unacceptable life-long morbidity. This multi-center collaborative effort focuses on identifying and understanding the fundamental mechanisms leading to high-risk childhood cancers, including how these malignancies evolve to evade the immune system and resist modern therapies. These discoveries will subsequently be translated into novel new immunotherapeutic strategies for children, adolescents and young adults with cancer, which are predicted to improve cure rates while diminishing the long-term toxicity experienced by survivors.

Immunogenomics to Create New Therapies for High-Risk Childhood Cancers

The St. Baldrick’s Foundation – SU2C Pediatric Cancer Dream Team is a collaboration between pediatric cancer researchers in the largely disparate disciplines of cancer genomics and immunotherapeutics. The team will focus on developing new, targeted immunotherapeutics for the most difficult-to-cure childhood cancers.

New classes of therapeutics are needed to improve survival of children with cancer and decrease the physical, emotional, and financial life-altering costs of curative therapies. The Team has used new technologies in the field of cancer genomics, epigenetics and proteomics to discover and validate new targets for immunotherapy. They have built new antibodies, antibody-drug conjugates and CAR T cells to attack these targets. The team has innovated in developing new immunotherapies, discovering basic mechanisms of effectiveness (or lack thereof) in both antibody and cellular engineering, and developed novel methods to monitor clinical effectiveness and toxicity. The team has opened 25 clinical trials and have treated 688 pediatric patients with cancers that have resisted treatment. They demonstrated the potency of immunotherapy against acute lymphocytic leukemia (ALL), as well as defined mechanisms for how these cancers cells develop resistance. They have also made progress against childhood solid cancers, with many emerging therapeutics just entering the clinics, or scheduled to enter testing over the next one to three years.

Teaching
OpenClose

Teaching Interest

As discipline lead for gastrointestinal pathology at Vancouver General Hospital, Dr. Schaeffer is actively involved in training programs for both medical students and residents.

Takei, Fumio

Takei, Fumio

PhD

Academic Rank(s): Professor, UBC, Distinguished Scientist

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Infectious Diseases and Immunology Microbiology

Clinical Interests:

Short Bio
OpenClose

Takei Lab

Dr. Takei received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. He has been working on innate lymphocytes for over 30 years. From 1990 to 2010, he mainly worked on natural killer (NK) cell receptors for MHC class I and regulation of NK cell functions and development. In 2010, he found a unique lymphocyte population, which is now termed group 2 innate lymphoid cell (ILC2), in mouse lungs. He showed that lung ILC2s play a key role in allergic lung inflammation. He is currently investigating the regulation of ILC2 functions and functional and developmental relationship between ILC2s and other lymphocytes.

Credentials
  • Professor, Pathology & Laboratory Medicine, University of British Columbia (UBC)
  • Associate Member, Medical Genetics, University of British Columbia (UBC)
  • Associate Member, Microbiology, University of British Columbia (UBC)

 

Academic
OpenClose

Academic Background

  • BSc, University of Tokyo, Tokyo, Japan, Biochemistry. 1968
  • PhD, University of British Columbia, Vancouver, BC, Immunology. 1976
  • Postdoctoral Fellow, University of British Columbia, Microbiology, 1977
  • Postdoctoral Fellow, MRC Laboratory of Molecular Biology, Cambridge, England. 1979

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

The innate lymphoid cell (ILC) family comsists of cytotoxic natural killer (NK) cells and cytokine-producing helper-like ILCs, which are further divided into three groups based on the cytokines they produce and the expression of key transcription factors. Currently, we are mainly interested in group 2 ILCs. We previously found ILC2s in mouse lungs and shown them to produce large amounts of Th2-type cytokines that drive l allergic inflammation (Halim et al. Immunity 2012a). We also developed ILC2-deficient mice and shown that ILC2s are critical for allergen-induced lung inflammation (Halim et al. Immunity 2012b). ILC2s also promotethe differentiation of naïve CD4+ T cells into Th2 cells (Halim et al. Immunity  2014). More recently, we have shown that activated lung ILC2s acquire antigen non-specific memory functions and drive severe allergic lung inflammation upon allergen re-exposure (Martinez-Gonzalez et al. Immunity 2018).

Our current research projects include:

  1. Investigation of ILC2 heterogeneity by single cell RNA sequencing, multi-color flow cytometry and functional analyses.
  2. Studies on the development and activation of lung ILC2s in the neonatal period and their role in adult lung immunity.
  3. Studies on tissue resident versus migratory ILC2s and their role in various inflammatory diseases.
  4. Analyses of ILC3s in mouse lungs.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Watson, Peter

Portrait photo of Peter Watson

Watson, Peter

MA MB BChir (Univ of Cambridge, UK) FRCPC

Academic Rank(s): Professor, UBC | Senior Scientist, Deeley Research Centre | Director Biobanking & Biospecimen Research Services (BBRS)

Affiliation(s): BC Cancer Agency, Victoria | CentreDept. of Biochemistry and microbiology, University of Victoria

Research and Scholarly Interests: Cancer, Molecular Pathology and Cell Biology, Scholarship of Teaching of Education Research, Professional Contributions, Molecular Pathology and Cell Biology Cancer, Diagnostic Breast Pathology, Anatomic Pathology

Clinical Interests:

Short Bio
OpenClose

Dr. Peter H. Watson is a Professor in the Department of Pathology, BC Cancer and the University of British Columbia and he is director of the BC Cancer Biobanking and Biospecimen Research Services.

Dr. Watson combines a clinical practice as a breast pathologist with a research laboratory based at the Deeley Research Center and an interest in the molecular pathology of solid tumors and in the development of biobank resources for health research. His laboratory made early contributions to approaches and application of molecular technologies to tissues and the program currently focuses specifically on the biology of biomarkers of breast tumour progression and the role of immune-tumor interactions in determining response to therapies.

In addition to directing the BC Cancer Biobanking and Biospecimen Research Services Program and he leads the Canadian Tissue Tumour Repository Network (CTRNet) .

 

Academic
OpenClose

Academic Background

  • BA (Natural Sciences), Cambridge University, 1978
  • MA, Cambridge University, 1982
  • MB BChir, Cambridge University, 1983
  • FRCPC (Anatomic Pathology), University of Manitoba, 1988

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Primary Research Area Molecular Pathology and Cell Biology Cancer
  • Secondary Research Area Education and Utilization Research
  • Cancer
  • Diagnostic Breast Pathology
  • Anatomic Pathology

Dr Peter Watson’s Laboratory:
Our laboratory is located at the Deeley Research Centre, BC Cancer Victoria Center (https://www.bccrc.ca/dept/drc/). Our focus is on the molecular pathology of breast cancer and biobanking in support of cancer research (https://www.bccrc.ca/dept/drc/services/biobanking-and-biospecimen-research-services) involving active interactions and collaborations with other cancer research laboratories and groups within the BC Cancer and other institutions.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Wright, Joanne

Wright, Joanne

BSc, MD (Alta.), FRCPC

Academic Rank(s): Professor Emeritus, UBC | Member, VCHRI, Institute for Heart+Lung Health

Affiliation(s): St. Paul’s Hospital

Research and Scholarly Interests: Cardiovascular and Pulmonary, Respiratory

Clinical Interests:

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • FRCP(C) – Anatomical Pathology. 1978
  • MD, University of Alberta. 1974
  • BSc, University of Alberta. 1972

Awards and Recognition

Publications

Selected Publications

  • Hackett TL, Shaheen F, Zhou S, Wright JL, Churg A. Fibroblast STAT 4 drives cigarette smoke induced airway fibrosis. Am J Respir Cell Mol Biol 2014;
  • Zhou S, Wright JL, Liu J, Sin DD, Churg A. Aging does not enhance experimental cigarette smoke induced COPD in the mouse.   PLOS 1 2013 8(8) e71410 Epub Aug 2 2013.
  • Wright JL, Churg A. Pathological findings in fatal and non-fatal asthma. Academic Forensic Pathol 2013.
  • Hui P, Mattman A, Wilcox PG, Wright JL, Sin DD. Immunoglobulin G4-related lung disease: A disease with many different faces. Can Respir J 2013; 20: 335-338.
  • Preobrazhenska O, Wright JL, Churg A. Regional heterogeneity in murine lung fibroblasts from normal mice or mice exposed once to cigarette smoke. PLoS One. 2012;7(6):e39761.
  • Yoon HI, Li Y, Man SF, Tashkin D, Wise RA, Connett JE, Anthonisen NA, Churg A, Wright JL, Sin DD. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest. 2012 Oct;142(4):893-99.
  • Churg A, Marshall CV, Sin DD, Bolton S, Zhou S, Thain K, Cadogan EB, Maltby J, Soars MG, Mallinder PR, Wright JL. Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jan 1;185(1):34-43.
  • Churg A, Sin DD, Wright JL. Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use? Am J Respir Cell Mol Biol. 2011 Dec;45(6):1111-5.
  • Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, Golbidi S, Churg AM. Statin Reverses Smoke-induced Pulmonary Hypertension and Prevents Emphysema but Not Airway Remodeling. Am J Respir Crit Care Med. 2011 Jan 1;183(1):50-8.
  • Wright JL, Churg A. Animal models of cigarette smoke-induced chronic obstructive pulmonary disease. Expert Rev Respir Med. 2010 Dec;4(6):723-34.
  • Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology. 2010 Sep 21. doi: 10.1111/j.1365-2559.2010.03650.x.
  • Tazelaar HD, Wright JL, Churg A. Desquamative interstitial pneumonia. Histopathology. 2010 Sep 21. doi: 10.1111/j.1365-2559.2010.03649.x.
  • Wright JL, Tazelaar HD, Churg A. Fibrosis with emphysema. Histopathology. 2010 Sep 21. doi: 10.1111/j.1365-2559.2010.03648.x.
  • Churg A, Müller NL, Wright JL. Respiratory bronchiolitis/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med. 2010 Jan;134(1):27-32. Review.
  • Churg A, Zhou S, Wang X, Wang R, Wright JL. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol. 2009 Apr;40(4):482-90.
  • Churg A, Zhou S, Preobrazhenska O, Tai H, Wang R, Wright JL. Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am J Respir Cell Mol Biol. 2009 Mar;40(3):268-76.
  • Lewis EC, Mizrahi M, Toledano M, Defelice N, Wright JL, Churg A, Shapiro L, Dinarello CA. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16236-41.
  • Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L1-15.
  • Wright JL, Churg A. Animal models of COPD: Barriers, successes, and challenges. Pulm Pharmacol Ther. 2008 Oct;21(5):696-8.
  • Wright JL, Postma DS, Kerstjens HA, Timens W, Whittaker P, Churg A. Airway remodeling in the smoke exposed guinea pig model. Inhal Toxicol. 2007 Sep;19(11):915-23.
Research
OpenClose

Research Interest

  • Role of inflammation in the pathogenesis of chronic obstructive pulmonary disease.
  • Airways disease in association with mineral dusts and fumes.
  • Pulmonary vascular disease as a consequence of cigarette smoking
  • Respiratory

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Yang, Decheng

Yang, Decheng

PhD (Univ. of Illinois )

Academic Rank(s): Professor Emeritus

Affiliation(s): St. Paul’s Hospital, HLI, PHCRI

Research and Scholarly Interests: Cardiovascular and Pulmonary, Infectious Diseases and Immunology Microbiology

Clinical Interests:

Short Bio
OpenClose

Dr. Decheng is a microbiologist/virologist. He received his B.Sc. degree in microbiology at Nankai University, PRC. He conducted his graduate studies at the University of Illinois at Urbana-Champaign, where he received his Ph.D. in molecular microbiology. He also received his postdoctoral training at the University of Illinois. He joined the Department of Pathology and Laboratory Medicine as an Assistant Professor in 1995. Currently, he is a Professor at the Department, and a Principal Investigator at the Center for Heart and Lung Innovation, St. Paul’s Hospital. Dr. Yang is also a Member of the UBC Center for Microbial Diseases and Host Defense Research. His research on enteroviral pathogenesis of heart diseases is continuously supported by Canada Institute of Health Research, National Sciences and Engineering Research Council of Canada, and Heart and Stroke Foundation of Canada. He has published over 100 basic research papers, a virology book (RNA Viruses: Host Gene Responses to Infections) and 17 book chapters in viral pathogenesis.

 

Academic
OpenClose

Academic Background

  • University of Illinois: Postdoctoral training in Molecular Microbiology
  • University of Illinois: Ph.D. in Molecular Microbiology
  • University of Illinois: M.Sc. in Plant Pathology
  • Nankai University: B.Sc. in Microbiology

Awards and Recognition

Publications

https://pubmed.ncbi.nlm.nih.gov/?term=yang%20d%20CVB3 

Selected Publications

Research
OpenClose

Research Interest

Dr. Decheng Yang’s research programs focus on molecular pathogenesis of coxsackievirus-induced myocarditis and dilated cardiomyopathy. The ongoing research projects include: 1) molecular mechanism of coxsackievirus replication, specifically focusing on the identification of cellular 5’TOP (Terminal oligopyrimidine tract) mRNAs in the regulation of viral transcription and translation. 2) Epigenetic analysis of N6-methyladenosine (m6A) methylation of viral and cellular mRNAs. This project aims to determine the effect of RNA m6A methylation on viral propagation and pathogenesis, and 3) Host gene response to viral infection: by using an inducible heart-specific NFAT5 (nuclear factor of activated T cells 5) knockout mice as a model system, Dr. Yang’s group focuses on study of host-viral interaction, particularly on the roles of NFAT5 and viral proteases in the pathogenesis of virus-induced heart diseases. These studies aim to identify key genes involved in host immune response signaling pathways leading to cardiomyocyte injury and heart dysfunction. The identified novel genes may serve as potential targets to design nucleic acid-based therapeutics (siRNA, antisense oligo and artificial microRNA) for the treatment of the disease.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

  • Med 570: Viral myocarditis and treatments
  • Path 521: Small RNAs in regulation of gene expression and diseasesy
  • Path 438: Directed studies

Wellington, Cheryl

Wellington, Cheryl

PhD

Academic Rank(s):Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine, UBC

Research and Scholarly Interests: Alzheimer disease, dementia, metabolism, cardiovascular system, neurodegeneration, concussion, traumatic brain injury

Clinical Interests: Brain Injury & Repair; Learning/Memory & Dementias

Short Bio
OpenClose

Dr. Wellington is a basic research scientist whose research interests focus on three common genetic and environmental risk factors for dementia, including apolipoprotein E (apoE) metabolism, history of traumatic brain injury (TBI), and cerebrovascular dysfunction.

Dr. Wellington holds leadership positions in both the dementia and neurotrauma communities, including the Canadian Traumatic Brain Injury Research Consortium, the International Traumatic Brain Injury Research Consortium, the Canadian Consortium for Neurodegeneration in Aging, and the AstraZeneca ApoE Alzheimer Disease Academic Alliance.

https://ca.linkedin.com/in/cheryl-wellington-81b03516

Wellington Lab Website

Academic
OpenClose

Academic Background

  • PhD, University of British Columbia, Microbiology. 1991
  • BSc, University of Alberta, Microbiology (1st Class Honors). 1985

Awards and Recognition

Publications

Publications

Research
OpenClose

Research Interest

Dr. Wellington is internationally recognized for her work on lipid and lipoprotein metabolism in the brain, and her group has made key contributions to the understanding of the role of apolipoprotein E (apoE) in Alzheimer’s Disease. ApoE is the major cholesterol carrier in the brain and the best established genetic risk factor for typical late-onset Alzheimer’s Disease. ApoE also plays a critical role in repair of damaged neurons after TBI. Dr. Wellington’s program also is closely linked with initiatives exploring the contributions of the vascular system and metabolic disease to dementia.

Additionally, Dr. Wellington’s group has recently developed an entirely novel, non-surgical animal model of concussion that for the first time, accurately mimics the biomechanics and the neuropathology of human head injury. Her current research projects include drug discovery efforts to increase apolipoprotein function in the brain for application to both Alzheimer’s Disease and TBI, understanding how movement of the head and brain after TBI correlate with behavioural and neuropathological outcomes, and tissue engineering approaches to investigate cerebrovascular function in health and disease.

Dr. Wellington’s research interests are highly multipdisciplinary with major efforts in the fields of Alzheimer’s Disease (AD) and Traumatic Brain Injury (TBI). With respect to both AD and TBI programs, her laboratory is the leading Canadian site for research on blood biomarkers using the Simoa platform, as she is the first in Canada to operationalize the Quanterix Simoa HD-1 Analyser. Her lab’s first paper using this platform to study serum tau as a biomarker in pediatric TBI was published online in June 2019 in Lancet Child and Adolescent Health. Dr. Wellington’s work on AD focuses mainly on how lipoproteins affect AD pathogenesis, with major programs focused on apolipoprotein E (apoE) and apoA-I, which is the major lipoprotein found on circulating high-density lipoprotein (HDL; the good cholesterol). For the AD program, her team uses a combination of animal models and in vitro platforms, including pioneering a human-based 3D tissue engineered model of perfusable cerebral vessels surrounded by astrocytes and, now, neurons. Along with Dr. Peter Cripton, a Mechanical Engineer, her laboratory developed the CHIMERA (Closed Head Model of Engineered Rotational Acceleration) animal model of TBI that is currently operational for mice, rats and ferrets. Thus far, this program has produced 9 peer-reviewed primary papers with 4 additional manuscripts under review. Importantly, the Wellington lab is committed to facilitating the dissemination of this platform to both academia and industry through licensing agreements. To date, they have completed 15 licensing agreements, which include building a CHIMERA device for the client, shipping, and traveling to the client’s facility to install CHIMERA and train new users on this platform.

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Bryce, Elizabeth

Bryce, Elizabeth

BSc, (Regina), MD, (Sask.), FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): VGH/VCHRI

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Scholarship of Teaching of Education Research, Medical Microbiology, Infection Control

Clinical Interests:

Short Bio
OpenClose

Dr. Elizabeth Bryce is a Medical Microbiologist at Vancouver Coastal Health Acute. She is dually qualified in Medical Microbiology and Internal Medicine and is a Clinical Professor at the University of British Columbia. Elizabeth is the past co-chair of the Canadian Nosocomial Infection Surveillance Program as well as a past co-chair for the Provincial Infection Control Network of British Columbia. Dr. Bryce is one of the founding members of the UBC Certificate in Infection Control as well as several on-line educational modules on this topic. She has a primary interest in environmental infection prevention and control. She has been recognized for her work with the YMCA Woman of Distinction in Research, the Sciences and Technology award (2022); the David Hardwick Lifetime Achievement Award (2021);​ the Canadian Coalition for Healthcare Infection Reduction Leadership Award (2020) and an Honorary Doctorate of Science from the University of Regina (2018).

 

Academic
OpenClose

Academic Background

  • BSc (Honours), University of Regina, Regina, SK. 1978
  • MD, University of Saskatchewan, Saskatoon, SK. 1983
  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC), Internal Medicine. 1988
  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC), Medical Microbiology. 1991

Awards and Recognition

Publications

Selected Publications

  • Nakhaie D, Williams T, Velapatino B, Bryce E, et al An Engineered Nanocomposite Copper Coating with Enhanced Antibacterial Efficacy bioRxiv, 28 Apr 2022  DO  – 10.1101/2022.04.28.489879 (in publication)​
  • Bryce EA, Velapatino B, Donnelly-Pierce T, et al  Evaluating the antimicrobial activity of copper surfaces against Pseudomonas aeruginosa and Staphyococcus aureus 1 year after use in a microbiology laboratory.  J Hosp Infect 2022;123:186-188.
  • Atiba N, Kassimatis J, Estoque J et al. Environmental detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from medical equipment in long-term care facilities undergoing COVID-19 outbreaks.  Am J Infect Control 49(2): 265-268, 2021 02.
  • Kotwa J, Jamal AJ, Mbareche H et al, Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada  medRxiv. 2021 May 20. doi: 10.1101/2021.05.17.21257122.
  • Hurlburt AW, DeKleer R, Bryce E.  Clearing the air:  addressing air clearance times for infectious aerosols in healthcare facilities.  Infect Cont Hosp Epid 2021;42:1-6
  • Cooper J, Himaras Y, Wong T, Bryce E.  Evaluation of a new sink design incorporating ozonated water.  J Hosp Infect 2020:104:497-502
  • Bryce EA, Velapatino B, Akbari Khorami H, et al.  In vitro evaluation of antimicrobial efficacy and durability of three copper surfaces used in healthcare.  Biointerphases 2020;10:15 doi 10.1116/1.5134676
  • Cheng L, Zurberg T, Kinna J, Acharya K, Warren J, Shajari, Forrester L, Bryce E.  Using scent detection dogs to identify environmental reservoirs of Clostridium difficile:  lessons from the field.  Can J Inf Cont 2019;34:93-95
  • Chai J, Donnelly T, Wong T, Bryce E.  Environmental sampling of hospital surfaces: assessing methodological quality.  Can J Inf Control 2018;33:138-145
  • Liautaud A, Adu PA, Yassi A, et al.  Strengthening human immunodeficiency virus and tuberculosis prevention capacity among South African healthcare workers: a mixed methods study of a collaborative occupational health program.  Saf Health Work 2018;9:172-179
  • Colindres CV, Bryce E, Coral-Rosero P, et al.  Effect of effort-reward imbalance and burnout on infection control among Ecuadorian nurses.  Int Nurs Rev 2018;65:190-199.
  • Malotle MM, Spiegel JM, Yassi A, Ngubeni D, O’Hara LM, Adu PA, Bryce EA, Mlangeni N, Gemell GSM, Zungu M. Occupational tuberculosis in South Africa are health care workers adequately protected?  Public Health Action 2017;21:258-267.
  • Bryce E, Zurberg T, Zurberg M, Shajari S, Roscoe D.  Identifying environmental reservoirs of Clostridium difficile with a scent detection dog: preliminary evaluation.  J Hosp Infect 2017;97:140-145.
  • O’Hara LM, Yassi A, Zungu M, Malotle M, Bryce EA et al.  The neglected burden of tuberculosis disease among health workers: a decade-long cohort study in South Africa.  BMC Infect Dis 2017;7:547 doi:10.1186/212879-017-2659-3.
  • Stefanovic A, Roscoe D, Ranasinghe R, Wong T, Bryce E, et al.  Performance assessment of urine flow cytometry (UFC) to screen urines to reflex to culture in immunocompetent and immunosuppressed hosts.  J Med Microbiol 2017;66:1308-1315.
  • O’Hara LM, Yassi A, Bryce EA et al.  Infection control and tuberculosis in health care workers: an assessment of 28 hospitals in South Africa.  Int J Tuberculosis and Lung Dis  2017:21:320-326.
  • Am J Infect Control 49(2): 265-268, 2021Hon CY, Danyluk Q, Bryce E, Janssen B, Neudorf M, Yassi A.    Comparison of qualitative and quantitative fit-testing results for three commonly used respirators in the healthcare sector.  J Occup Environ Hyg 2017;14;175-179
Research
OpenClose

Research Interest

Innovation in Infection Prevention and Control
I am very committed to exploring new technologies for infection prevention, particularly those that employ human factors engineering principles. For example, I was the lead investigator for a project assessing the role of a novel nasal photodisinfection therapy for the prevention of surgical site infections. Our project has won both the National Association of Medical Microbiology and Infectious Diseases Innovation Academy award in 2012 as well as the International Conference on Prevention and Control of Infections (Geneva) 2013 Innovation Academy award. We have also assessed and integrated ultraviolet C disinfection into our major facility and presented on our findings at several national conferences. We are currently assessing the role of human factors engineering in the in-built design of healthcare facilities and its role in the procurement process. We have completed a Genome BC grant to assess self-disinfecting surfaces in a bone marrow transplant unit using both gene sequencing as well as traditional microbiology to assess changes in the microbiome of the environment, patient and healthcare worker. I completed a Vancouver and UBC Hospital Foundation grant to assess different formulations of copper surfaces for antimicrobial efficacy, durability and materials compatibility within a healthcare environment. I am now involved in a similar project with Vancouver Translink and Toronto Transit Authority.

I am a cofounder of the VCH Biomedical Canine Detection Team initially focusing on the detection of C.difficile in the environment. This has been successfully transferred as a regular part of environmental screening at VCH and in the Fraser Region. In collaboration with Health Canada, we successfully trained canines to detect COVID variants from a number of patient samples and environmental samples.

 

Surveillance:
VGH is one of the founding institutions of the Canadian Nosocomial Infection Surveillance Program. I am a past co-chair of this national surveillance program as well as a past Chair of the Working Group on carbapenem resistant gram negative bacilli. I was also the co-director of the Provincial Infection Control Network of BC whose task is to coordinate infection control surveillance, guideline development and education across the province.

 

Infection Control Workplace Assessment and Program Development:
I have developed algorithms for patient isolation and selection and use of personal protective equipment to prevent transmission of gastrointestinal and respiratory communicable infections. These have been adapted for use in South Africa, Costa Rica, Ecuador, and Trinidad/Tobago. Our team has also developed and refined workplace assessment tools and training of Infection Control Practitioners to conduct process improvement activities related to these audits; these are now being used internationally. We have obtained three grants related to this work, the most recent a three year CIHR grant to implement the audits and build capacity for occupational health and infection control programs in South Africa. We are committed to promoting health equity in under-resourced countries specifically promoting/advancing infection prevention and occupational health capacity in a respectful and collaborative manner.

 

Infection Control Education:
Four grants have been awarded in the past in recognition of the importance of developing a University accredited Certificate in Infection Control. This Certificate comprises four courses and we enrol students both nationally and internationally; the courses are fully subscribed. Three additional grants have been awarded to develop and evaluate an on-line infection control module for all healthcare workers. One of these was a three-year CIHR grant for assessment of an on-line infection control module that teaches basic principles to all healthcare workers. Subsequently, this module is required for all new employees and for all physicians at Vancouver Coastal Health and many facilities in BC use the module which is Creative Commons Licensed. The Pan American Health Organization has also translated this basic on-line infection control module into Spanish for distribution throughout South America. The Government of South Africa is using the module for training of all healthcare workers in Free State. Most recently Saudi Arabia will use the module for training purposes and the World Health Organization references it as a resource.

 

Emerging Infectious Diseases:
I was the Cofounder of the original VCH Biological Response Advisory Team whose templates have been adopted by Health Canada. In recognition of this work, our team was awarded a grant from Health Canada to develop smallpox contingency planning guidelines. Following on that work, I became a member of the BC Emerging Infectious Diseases Committee and Pandemic Influenza Advisory Committee. I was seconded to work in Toronto on the SARS Medical Advisory Committee for six weeks during the height of the outbreak. I was one of a multidisciplinary group to receive a Pan-American Health Organization grant to assist with development of a management plan for biological events in Trinidad during the Summit of the Americas and the PanAm Games in 2009. I was a member of the Public Health Agency of Canada Annex F Pandemic Planning Committee that developed guidelines prior to and during pandemic H1N1, a member of the Clinical H1N1 Advisory Group as well as a member of the VCH Pandemic Planning Committee. I was the infection prevention lead for Ebola planning in our acute care facilities at VCH and currently part of the VCH All Hazards team to proactively manage unusual communicable disease exposure events. More recently, I have been the Infection Control Medical Lead for COVID at Vancouver Acute.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

UBC Certificate On-line Infection Control Program

Garg, Arun

Garg, Arun

PhD, MD, FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): Royal Columbian Hospital

Research and Scholarly Interests: Knowledge translation, Professional Contributions, Clinical Biochemistry of Feto-Placental Unit, Endocrine/Metabolic Investigation, Laboratory Utilization Protocols, Public Policy Development on Health Care, Technology Evaluation, Utilization Management; Point of care Testing

Clinical Interests:

Short Bio
OpenClose

Dr Arun Kumar Garg is a Consultant Medical Biochemistry at Fraser Health‘s Department of Laboratory Medicine and Pathology. His interest and extensive experience allows him to have global practice and engagement. He has served as Program Medical Director for Fraser Health Regional Department of Laboratory Medicine for 20 years and Division Head of Medical Biochemistry for over 30 years. He is also Clinical Professor of Pathology in the Faculty of Medicine at the University of British Columbia (www.ubc.ca/pathology) and Director of the Cooperation and Engagement of the office of Global medicine. Adjunct Professor of Clinical Services in the Faculty of Health Science at Simon Fraser University.

He holds a Doctor of Philosophy in Biochemistry from the Univ of Saskatchewan, Doctor of Medicine from the University of British Columbia, Fellowship in Medical Biochemistry from Royal College of Physicians and Surgeons of Canada. And a Fellow of the American College of Pathologist.

Founded Canada India Network Society ( www.thecins.org; twitter/thecins; facebook ) in 2010, to build strong links between Canada and India in Life Sciences and Health services. . He holds the position of Program Medical Director for South Asian Health Institute in Fraser Health (www.fraserhealth.ca/sahi;).

He has been active in many voluntary organizations over last 45 years including as President of Doctors of BC (1993-94) and many senior leadership positions in academic (BCIT,SFU,UBC) and professional institutes.(CMA, BCMA, Inst of Health Care Transformation and Sustainability, CAPIH, GAPIO, PISA etc) and business organizations ( BC Biomedical laboratories Ltd, DG Enterprises Ltd)

He has been recognized and awarded numerous honors, awards. Hon Doctor of Technology by BC, Inst of technology , first foundational recipient of Dr Don Rix Gold medal for life time contribution as leader by the Doctors of BC in 2013, life time leadership award from Cand Assoc of Physicians of Indian heritage, and Community award of health care leadership award from Dhristi magazine.

 

Academic
OpenClose

Academic Background

  • BSc, Agra University, India, Biology. 1962
  • MSc, Agra University, India, Organic Chemistry. 1964
  • MSc, University of Saskatchewan, Biochemistry. 1968
  • PhD, University of Saskatchewan, Biochemistry. 1970
  • MD, University of British Columbia. 1977
  • Fellow, Royal College of Physicians & Surgeons of Canada (FRCPC). 1980

Awards and Recognition

  • Don Rix Gold Medal Leadership Award,British Columbia Medical Association Awarded. 2011

Publications

Selected Publications

  • Familial Hypercholesterolemia: A call for Increased Awareness in the Asian Indian Population: A review article Sophia Wong and Arun K garg Austin J Clin Path 1,(20) 2014, p9.
  • Relationship of Sodium and Magnesium intakes to hypertension proven by 24 hour urinalysis in a South Indian population : Natesh Chidambaram,S Sethpathy,N Saravanan,Mari Mori,Yukio Yamori,Arun K Garg, Arun Chockalingam ;The J of Clinical Hypertension DOI 10.1111/jch.12361. 2014
  • Evaluating a Diabetes Self Management Support Peer Lead Training Program For the English and Punjabi Speaking South Asian Community in Vancouver, T. S. Tang, P. S. Sohal, A. K. Garg, Ahmad Al-Saraf, Chiman Chow; Diabetes Medicine D0110:1111/DMC 12179, July 2013.
  • Ahmad Al-Saraf, Chiman Chow, Arun K. Garg, Care Report; Bisalbuminemia Detected by Agarose Gel Electrophoresis, Clinical Biochemistry, 43 (2013) 534.
  • The Determination of Urinary Free and Conjugated Cortisol using UPLC-MS/MS; Dong Sheng Ming, John Heathcote, Arun Garg; Bioanalysis (2011) 3 (3), 301-312.
Research
OpenClose

Research Interest

  • Clinical Biochemistry of Feto-Placental Unit
  • Endocrine/Metabolic Investigation
  • Laboratory Utilization Protocols
  • Public Policy Development on Health Care
  • Technology Evaluation, Utilization Management; Point of care Testing

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Overseas the BC Bio / Royal Columbian Hospital Rotations

Gown, Allen

Gown, Allen

BS (N.Y.), MD (Yeshiva)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Medical Director, PhenoPath Laboratories

Affiliation(s): PhenoPath Laboratories

Research and Scholarly Interests: Cancer, Molecular Pathology and Cell Biology

Clinical Interests:

Short Bio
OpenClose

Director and Chief Pathologist at PhenoPath Laboratories, a Seattle-based national reference immunohistochemistry laboratory founded by Dr. Gown in 1998. He is Clinical Professor of Pathology at the University of British Columbia, Vancouver, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle.

Dr. Gown is an internationally recognized authority in the field of diagnostic immunohistochemistry, having published many key
papers in this field over the past 20 years. He serves as a member of the Editorial Board for several pathology journals, and regularly gives workshops in diagnostic immunohistochemistry under the auspices of the United States Canadian Academy of Pathology and the American Society of Clinical Pathologists.

 

Academic
OpenClose

Academic Background

  • BSc, State University of New York at Stony Brook, New York, Magna cum laude (Physics). 1971
  • MD, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York. 1975

Awards and Recognition

Publications

Selected Publications

  • Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, Gown AM, Habel LA. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010 Oct 1;28(28):4300-6. Epub 2010 Aug 9.
  • Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010 May;176(5):2067-81. Epub 2010 Apr 2.
  • Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, Puligandla B, Alshak NS, Goldstein LC, Gown AM, Schnitt SJ, Habel LA. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec;33(12):1802-8.
  • Osamura RY, Gown AM. Personalized medicine-molecular targeted cancer therapy. J Cell Mol Med. 2009 Nov-Dec;13(11-12):4285. Epub 2009 Aug 19.
  • Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, O’Malley F, O’Brien AE, SenGupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):375-82.
  • Gown AM. Tweaking and nudging toward improved-IHC quality. Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):363-5.
  • Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009 Aug 20;27(24):3881-6. Epub 2009 Jul 20.
  • Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009 Aug;133(8):1317-31.
  • Deen S, Griffith OL, Masoudi H, Gown A, Jones SJ, Wiseman SM. Anaplastic thyroid carcinoma exhibits intratumoral molecular homogeneity for a therapeutic target panel. Anticancer Res. 2009 Jul;29(7):2437-44.
  • Fleming JN, Shulman HM, Nash RA, Johnson PY, Wight TN, Gown A, Schwartz SM. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One. 2009 Jul 9;4(7):e6203.
Research
OpenClose

Research Interest

  • Molecular Pathology
  • Cancer

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Kleinman, Steven

Kleinman, Steven

BSc (M.I.T.), MD (Calif., San Diego)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Adjunct Scientist, Canadian Blood Services, Senior Medical Advisor, American Association of Blood Banks (AABB)

Affiliation(s): Community (VIHA)

Research and Scholarly Interests: Blood research, Transfusion medicine

Clinical Interests:

Short Bio
OpenClose

Dr. Kleinman is an internationally recognized expert in the field of blood safety.

Since 1996, he has been president of a transfusion medicine consulting company (Kleinman Biomedical Research) located in Victoria, BC whose clients include numerous blood collection organizations, government, and industry in both the US and Canada. He is also Clinical Professor of Pathology at U. British Columbia. He has published over 100 peer reviewed scientific articles and 18 book chapters and has co-edited a textbook in Transfusion Medicine. He has chaired the American Association of Blood Banks (AABB) Committee on Transfusion Transmitted Disease, the AABB Interagency Task Force on Bacterial Contamination of Platelets and the Consensus Panel of the 2004 Canadian Consensus Conference on TRALI.

 

Academic
OpenClose

Academic Background

  • Fellow, Cedars-Sinai Medical Center, Los Angeles, CA (Section on Blood Banking, Department of Clinical Pathology).  1981-1982
  • Chief Resident, Cedars-Sinai Medical Center, Los Angeles, CA (Clinical Pathology). 1980-1981
  • Resident, Cedars-Sinai Medical Center, Los Angeles, CA    (Pathology). 1977-1980
  • MD, University of California at San Diego, School of Medicine, La Jolla, CA. 1976
  • BSc, Massachusetts Institute of Technology, Cambridge, MA, Biology. 1972

Professional Qualifications

  • American Board of Pathology Certification in Blood Banking. 1982
  • American Board of Pathology Certification in Anatomic and Clinical Pathology. 1981
  • Medical License: State of California. 1978

Awards and Recognition

  • Owen Thomas Award, California Blood Bank Society. 2008
  • President’s Award, Society for the Advancement of Blood Management. 2005
  • Taft Schreiber Memorial Lectureship, Cedars-Sinai Medical Center, Los Angeles, CA. 2004

Publications

Selected Publications

  • Carrick DM, Norris PJ, Endres RO, Pandey S, Kleinman SH, Wright D, Sun Y, Busch MP. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion. 2011 Feb 18. doi: 10.1111/j.1537-2995.2010.03048.x. [Epub ahead of print].
  • Lee TH, Kleinman SH, Wen L, Montalvo L, Todd DS, Wright DJ, Tobler LH, Busch MP; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion. 2011 Feb 8. doi: 10.1111/j.1537-2995.2010.03035.x. [Epub ahead of print].
  • Klein HG, Dodd RY, Hollinger FB, Katz LM, Kleinman S, McCleary KK, Silverman RH, Stramer SL; for the AABB Interorganizational Task Force on XMRV. Xenotropic murine leukemia virus-related virus (XMRV) and blood transfusion: report of the AABB interorganizational XMRV task force. Transfusion. 2011 Jan 14. doi: 10.1111/j.1537-2995.2010.03012.x. [Epub ahead of print].
  • Rios JA, Schlumpf KS, Kakaiya RM, Triulzi DJ, Roback JD, Kleinman SH, Murphy EL, Gottschall JL, Carey PM. Blood donations from previously transfused or pregnant donors: a multicenter study to determine the frequency of alloexposure. Transfusion. 2010 Dec 23. doi: 10.1111/j.1537-2995.2010.02991.x. [Epub ahead of print].
  • Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, Devine D. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion. 2010 Dec;50(12):2592-606. doi: 10.1111/j.1537-2995.2010.02724.x.
  • Carrick DM, Johnson B, Kleinman SH, Vorhaben R, Chance SC, Lee JH, Roback JD, Pandey S, Sun Y, Busch MP, Norris PJ; for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion. 2010 Nov 18. doi: 10.1111/j.1537-2995.2010.02938.x. [Epub ahead of print].
  • Gottschall JL, Triulzi DJ, Curtis B, Kakaiya RM, Busch MP, Norris PJ, Glynn SA, Carrick D, Wright DJ, Kleinman S. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population. Transfusion. 2010 Oct 26. doi: 10.1111/j.1537-2995.2010.02913.x. [Epub ahead of print].
  • Blajchman MA, Glynn SA, Josephson CD, Kleinman SH; State-of-the Science Symposium Transfusion Medicine Committee. Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. Transfus Med Rev. 2010 Oct;24(4):259-85.
  • Endres RO, Kleinman SH, Carrick DM, Steele WR, Wright DJ, Norris PJ, Triulzi D, Kakaiya R, Busch MP; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010 Aug;50(8):1749-60. doi: 10.1111/j.1537-2995.2010.02589.x. Epub 2010 Feb 11.
  • Kakaiya RM, Triulzi DJ, Wright DJ, Steele WR, Kleinman SH, Busch MP, Norris PJ, Hillyer CD, Gottschall JL, Rios JA, Carey P, Glynn SA; National Heart, Lung, and Blood Institute (NHLBI) Retrovirus Epidemiology Donor Study-II. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010 Jun;50(6):1328-34. Epub 2010 Jan 8.
Research
OpenClose

Research Interest

  • Transfusion medicine with particular emphasis on transfusion-transmitted infections
  • Other adverse effects of blood transfusion, and how to use epidemiologic research data to formulate public and regulatory policy in blood transfusion safety

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Topics in transfusion medicine

Korbelik, Mladen

Korbelik, Mladen

BSc, MSc, PhD (Zagreb)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Emeritus Scientist

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Infectious Diseases and Immunology Microbiology, Knowledge translation, Molecular Pathology and Cell Biology, Tumor biology, Photodynamic therapy, Cancer immunotherapy, Radiobiology, Experimental oncology

Clinical Interests:

Short Bio
OpenClose

Upon completion of his PhD in Biology in 1979 at the University of Zagreb, Dr. Mladen Korbelik moved to Vancouver to undertake post-doctoral fellowship training at the British Columbia Cancer Research Centre. He subsequently was brought into the organization’s scientific staff and has been working on his own independent research program with the BC Cancer Agency for over 25 years now. Dr. Korbelik is presently a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Agency. He is a Board Member and a Founding Fellow of the PanAmerican Photodynamic Association. He is also on the Directorship Board of International Photodynamic Association.

 

Academic
OpenClose

Academic Background

  • PhD (Biology), University of Zagreb, Croatia, 1979
  • MSc (Experimental Biology), University of Zagreb, Croatia, 1974
  • BSc (Chemistry), University of Zagreb, Croatia, 1970

Awards and Recognition

Publications

Selected Publications

  • Korbelik, M., Banáth, J., Canals, D., Hannun, Y.A., Separovic, D.: Ceramide and sphingosine-1-phosphate act as photodynamic therapy-elicited damage-associated molecular patterns: Cell surface exposure. Int. Immunopharmacol., 20: 359-365, 2014.
  • Korbelik, M., Banáth, J., Zhang, W., Wong, F., Bielawski, J., Separovic, D.: Ceramide and sphingosine-1-phosphate/sphingosine act as photodynamic therapy-elicited damage-associated molecular patterns: Release from cells and impact on tumor-associated macrophages. J Anal Bioanal Tech S1: 009, 2014 (doi: 10.4172/2155-9872.S1-009).
  • Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., Bracci, L., Breckpot, K., Brough, D., Baque, A., Castro, M.G., Cirone, M., Colombo, M.I., Cremer, I., Demaria, S., Dini, L., Eliopoulos, A., Faggioni, A., Forment, S.C., Fučikova, J., Gabriele, L., Gaipl, U.S., Galon, J., Garg, A., Ghiringhelli, F., Giese, N.A., Guo, Z.S., Hemminki, A., Herrmann, M., Hodge, J.W., Holdenrieder, S., Honeychurch, J., Hu, H.-M., Huang, X., 2014
  • Boppana, NB, Kodiha, M., Stochaj, U., Lin, H.-S., Haimovitz-Friedman, A., Bielawska, A., Bielawski, J., Divine, G.W., Boyd, J.A., Korbelik, M., Separovic, D.: Ceramide synthase inhibitor fumonisin B inhibits apoptotic cell death in SCC17B human head and neck squamous carcinoma cells after Pc4 photosensitization. Photochem. Photobiol. Sci, 2014 (in press).
  • Lucas, L.J., Chen, X.K., Smith, A.J., Korbelik, M., Zeng, H., Lee, P.W.K., Hewitt, K.C.: Aggregation of nanoparticles in endosomes and lysosomes produce surface enhance Raman spectroscopy. J. Nanoparticles, 2014 (submitted).
  • Korbelik, M., Banáth, J., Saw, K.M., Zhang, W., Čiplys, E.: Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines. Frontiers in Tumor Oncology (submission October 2014).
  • Korbelik, M., Zhang, W., Saw, K.M., Szulc, Z.M., Bielawska, A. and Separovic, D.: Cationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors. J. Photochem. Photobiol. B:Biol. 126: 72-77, 2013.
  • Separovic, D., Breen, P., Boppana, N.B., Van Buren, E., Joseph, N., Kraveka J.M., Rahmaniyan, M, Li, L., Gudz, T.I., Bielawska, A., Bai, A., Bielawski, J., Pierce, J.S., Korbelik, M.: Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation. Int. J. Oncol. 43: 2064-2072, 2013 (doi: 10.3892/ijo.2013.2132).
  • Korbelik, M., Madiyalakan, R., Woo, T. and Haddadi, A.: Antitumor efficacy of photodynamic therapy using novel nanoformulations of hypocrellin photosensitizer SL052. Photochem. Photobiol., 88: 188-193, 2012.
  • Korbelik, M. and Merchant, S.: Photodynamic therapy-generated cancer vaccine elicits acute phase and hormonal response in treated mice. Cancer Immunol. Immunother., 61: 1387-1394, 2012.
Research
OpenClose

Research Interest

  • Cell biology
  • Tumor biology
  • Photodynamic therapy
  • Cancer immunotherapy
  • Radiobiology
  • Experimental oncology
  • (PDT) Photodynamic Therapy: My laboratory is involved in pre-clinical studies aimed at improving therapy of solid cancers. A major focus is on the investigation of the mechanism of antitumor effects of photodynamic therapy (PDT). This novel type of cancer treatment (which is now a regulatory approved clinical modality) is still under intense development. The research in my laboratory has contributed to the understanding of photosensitizer (i.e. phototoxic drug used for PDT) accumulation in tumors, particularly the role of serum proteins, tumor vasculature and tumor associated macrophages in this event. Our work has shown that PDT treatment of solid cancers elicits a strong host response, which contributes to the therapy outcome. We are studying the role of the engaged inflammatory effector systems, including neutrophils, complement and coagulation/fibrinolytic cascades.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Martinka, Magdalena

Martinka, Magdalena

MD (Lublin, Poland), FRCP(C)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Dermatopathologist, VGH

Affiliation(s): VGH/VCHRI

Research and Scholarly Interests: Skin Conditions, Cutaneous Lymphoma, Alopecia, Melanocytic Lesions, Prognostic Factors in Melanomas, Dermatopathology

Clinical Interests:

magda.martinka@vch.ca

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • FRCP(C). 1997
  • MD, Medical Academy, Lublin, Poland, General Physician. 1986

Awards and Recognition

Publications

Selected Publications

  • Bhandaru M, Ardekani GS, Zhang G, Martinka M, McElwee KJ, Li G, Rotte A.
    BMC Cancer. A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. 2014 Jun 3;14(1):398.
  • Bhandaru M, Martinka M, Li G, Rotte A. Loss of AMPKα1 expression is associated with poor survival in melanoma patients. J Invest Dermatol. 2014 Jun;134(6):1763-6.
  • Bhandaru M, Martinka M, Li G, Rotte A. Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma. Pigment Cell Melanoma Res. 2014 May;27(3):366-75. doi: 10.1111/pcmr.12212. Epub 2014 Feb 10.
  • Huwait H, Hijazi N, Martinka M, Crawford RI. The significance of Melan-A-positive pagetoid melanocytosis in dysplastic nevi. Am J Dermatopathol. 2014 Apr;36(4):340-3.
  • Al-Mohammedi F, Crawford RI, Martinka M. Biopsies of facial dermatoses made simple. Arch Pathol Lab Med. 2014 Apr;138(4):550-2.
  • Sjoestroem C, Khosravi S, Cheng Y, Safaee Ardekani G, Martinka M, Li G. DLC1 expression is reduced in human cutaneous melanoma and correlates with patient survival. Mod Pathol. 2014 Feb 21.
  • Al Jasser MI, Martinka M, Kalia S. Dermatofibroma mimicking melanoma dermoscopically. Clin Exp Dermatol. 2014 Jan;39(1):69-70.
  • Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ, Li G. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer. 2014 Jan 21;110(2):399-408.
  • Tang Y, Cheng Y, Martinka M, Ong CJ, Li G. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis. 2014 Jan;35(1):86-95.
  • Lu J, Tang Y, Farshidpour M, Cheng Y, Zhang G, Jafarnejad SM, Yip A, Martinka M, Dong Z, Zhou J, Xu J, Li G. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis. 2013 Dec;34(12):2778-88. doi: 10.1093/carcin/bgt318. Epub 2013 Sep 24.
Research
OpenClose

Research Interest

  • Cutaneous Lymphoma
  • Alopecia
  • Melanocytic Lesions
  • Prognostic Factors in Melanomas (Creating tissue microarrays to evaluate number of melanoma cases, dysplastic nevi and normal nevi for prognostic factors)
  • Dermatopathology

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Moore, Wayne G R

Moore, Wayne G R

BSc (Nfld.), MD(McG.), FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s):ICORD

Research and Scholarly Interests: Brain and Neuroscience, Multiple Sclerosis

Clinical Interests:

Short Bio
OpenClose

Affiliation with organizations and societies:

  • Medical Advisory Committee, Multiple Sclerosis Society of Canada
  • Vancouver General Hospital (VGH)

 

Academic
OpenClose

Academic Background

  • Fellow of the Royal College of Pathologists (UK). 2007
  • Certification in Neuropathology by the Royal College of Physicians and Surgeons of Canada. 1980
  • Certification in Neurology by the Royal College of Physicians and Surgeons of Canada. 1978
  • MD, CM, McGill University, Montreal, QC. 1972
  • BSc, Memorial University of Newfoundland, St. John’s, NL. 1968

Awards and Recognition

Publications

Selected Publications

  • Laule C, Pavlova V, Leung E, Zhao G, MacKay AL, Kozlowski P, Traboulsee AL, Li DKB, Moore GRW. Diffusely abnormal white matter in multiple sclerosis: Further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration. J Neuropathol Exp Neurol 72: 42-52, 2013.
  • Zhang Y, Moore GRW, Laule C, Bjarnason TA, Kozlowski P, Traboulsee A, Li DKB. Pathological correlates of MRI texture heterogeneity in multiple sclerosis. Ann Neurol 74: 91-99, 2013.
  • Wiggermann V, Hernández Torres E, Vavasour IM , Moore GRW, Laule C, MacKay AL, Li DKB, Traboulsee A, Rauscher A. Magnetic resonance frequency shifts during acute MS lesion formation. Neurology 81: 211-218, 2013.
  • Ford CC, Inglese M, Moore GRW. Using imaging technologies in MS. Predicting disease progression and response to therapy. The Science of MS Management 3: 1-15, 2013.
  • Moore GRW, Laule C. Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis. J Neuropathol Exp Neurol 71: 762-778, 2012.
  • Roefs AM, Waters PJ, Moore GRW, Dolman PJ. Orbicularis oculi muscle biopsies for mitochondrial DNA analysis in suspected mitochondrial myopathy. Br J Ophthalmol 96: 1296-1299, 2012.
  • Cook SD, Dhib-Jalput S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simon J, Sormani MP. Use of magnetic resonance imaging as well as clinical disease activity in the clinical evaluation of multiple sclerosis and assessment of its course. A report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care 14: 105-114, 2012.
  • Moore GRW, Esiri MM. The pathology of multiple sclerosis and related disorders. Diag Histopathol 17: 225-231, 2011.
  • Laule C, Vavasour IM, Leung E, Li DKB, Kozlowski P, Traboulsee AL, Oger J, MacKAy AL, Moore GRW. Pathological basis of diffusely abnormal white matter: Insights from magnetic resonance imaging and histology. Mult Scler 17: 144-50, 2011.
  • Kleinschmidt-DeMasters BK, Alassiri AH, Birks D, Newell K, Moore, GRW, Lillehei KO. Epithelioid versus rhabdoid gliomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol 2010;34: 341-354.
Research
OpenClose

Research Interest

Dr. Moore conducts research on the pathology of multiple sclerosis (MS). Dr. Moore is a Principal Investigator at ICORD and a Clinical Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He completed his B.Sc. at Memorial University of Newfoundland, and his M.D. at McGill University.

Clinical Service

Current Projects In My Lab Include

  1. Please contact Dr. Moore with inquiries.
Teaching
OpenClose

Teaching Interest

  • Served on Supervisory Committees for many MSc and PhD students in Departments of Pathology and Laboratory Medicine, and Neuroscience, University of British Columbia.
  • Teaching of numerous medical students, and neuropathology, anatomical pathology, clinical pathology, neurology and neurosurgery residents.

Morshed, Muhammad

Morshed, Muhammad

BSc, MSc (Dhaka), PhD (Yamaguchi)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Clinical Microbiologist, BCCDC

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Molecular Pathology and Cell Biology, Medical Microbiology,Cell Biology, Zoonotic, Spirochaetal Diseases

Clinical Interests:

Short Bio
OpenClose

Dr. Morshed received his PhD from the Yamaguchi University School of Medicine (Japan) in 1994. He completed his specialty training at the Research Institute of Tuberculosis in Tokyo and at the College of Natural Resources, University of California (Berkeley).

Dr. Morshed is recognized by the national and international research community for his expertise on spirochaetal diseases (Lyme disease, Syphilis, Helicobacter pylori). He has added significantly to the general knowledge and understanding of these diseases with more than 130-refereed scientific publications. His research focuses mainly on disease surveillance, test optimization and utilization on zoonotic and emerging pathogens.

Dr Morshed is a member of many provincial, national and international working groups and networks in the area of zoonotic and emerging pathogens and served on the executive boards of the Canadian College of Microbiologists (CCM) and Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID).

Dr Morshed is actively involved in undergraduate, graduate, and post-graduate educational programs at UBC and currently serves as coordinator of an undergraduate-level course on Medical Microbiology. On his recognition, Dr Morshed received an Excellence in Clinical Services Award from the UBC Department of Pathology & Laboratory Medicine in 2016. He was named a winner in the RBC Top 25 Canadian Immigrant Awards in 2017, received the Distinguished Microbiologist Award from the Canadian College of Microbiologists (CCM) in 2019 and became elected as an Expatriate Fellow by the Bangladesh Academy of Sciences (BAS) in 2020.

 

Academic
OpenClose

Academic Background

  • Canadian College of Microbiologists, Specialist Microbiologist Certification.  1998
  • PhD, Yamaguchi University, Japan, Medical Microbiology. 1994
  • MSc, University of Dhaka, Bangladesh, First Class in Microbiology. 1979
  • BSc (Honours), Dhaka Univ., Bangladesh, First Class in Botany. 1978

Awards and Recognition

Publications

For publications and citations, see Google Scholar.

Selected Publications

Research
OpenClose

Research Interest

Dr. Morshed’s primary research area is medical microbiology, infectious diseases and immunopathology; his secondary research area is molecular pathology and cell biology and zoonotic and spirochaetal diseases. His work includes a focus on modern diagnosis, the discovery of novel pathogens and the molecular epidemiology of zoonotic and emerging pathogens, particularly Borrelia burgdorferi, Treponema pallidum and Helicobacter pylori.

His laboratory at BCCDC is responsible for specialized serology testing, molecular testing and microbial fingerprinting, program evaluation and research. Currently his team is working on developing in-house nucleic acid testing as well as finding novel pathogens for vector-borne diseases.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

O’Connor, Robert

Portrait photo of Robert  O'Connor

O’Connor, Robert

MB, BCh, BAO (Dublin), FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Consultant Pathologist, BC Cancer Agency, Institute for Heart+Lung Health

Affiliation(s): Vancouver General Hospital

Research and Scholarly Interests:

Clinical Interests:

Short Bio
OpenClose

Dr. O’Connor received his medical training at Trinity College, Dublin, Ireland from 1972 to 1978 (MB, BCh, BAO).  He first came to Canada for a Rotating Internship at the Memorial University of Newfoundland in 1978.  He completed a Residency in Anatomic Pathology at the University of Western Ontario (1979-1980), a Residency in Combined Anatomic Pathology and General Pathology at Dalhousie University (1980-1983), and was a Fellow in Anatomic Pathology at the University of Manitoba (1983-1984).

Dr. O’Connor received FRCPC in Anatomic Pathology in 1984.  He began his career in Vancouver in 1999 when he assumed the positions of Consultant Pathologist at the B.C. Cancer Agency and Consultant Pathologist, Lung, Pleura and Mediastinum, at the Canadian Reference Centre for Cancer.  He continues to hold both positions.  He was appointed to the rank of Clinical Associate Professor in  the UBC Department of Pathology and Laboratory Medicine in 1999 and promoted to the rank of Clinical Professor in 2003.

 

Academic
OpenClose

Academic Background

  • MB, BCH, BAO, Trinity College, Dublin, Ireland. 1978

Professional Qualifications

  • Diplomate, American Board of Pathology, Cytopathology, 1997
  • FRCPC – Anatomic Pathology, 1984
  • Diplomate, American Board of Pathology – Anatomical Pathology, 1984
  • College of Physicians and Surgeons of Manitoba, Specialist Register, Pathology, 1984-
  • Fellow in Anatomic Pathology, University of Manitoba, Winnipeg, Manitoba. Subspecialty responsibilities in Pulmonary Pathology, 1983-1984
  • Provincial Medical Board of Nova Scotia, Full, unrestricted medical license, 1984
  • Postgraduate courses, Dalhousie University, Halifax, Nova Scotia, 1983
    – Pathobiology Course (502)
    – Clinical Chemistry Course (501)
  • Resident, Combined Anatomic and General Pathology, Dalhousie University, Halifax, Nova Scotia, 1983
  • Resident, Anatomic Pathology, University of Western Ontario, London, Ontario, 1980
  • LMCC, 1979
  • Rotating Internship, Memorial University of Newfoundland, 1979
  • ECFMG, 1977

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Pryzdial, Edward

Pryzdial, Edward

PhD

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Senior Scientist, Medical Affairs and Innovation, Canadian Blood Service

Research and Scholarly Interests: Blood research, Cardiovascular and Pulmonary, Infectious Diseases and Immunology Microbiology, Virus-Induced Coagulopathy, Clot-Busting Enhancers

Clinical Interests:

Short Bio
OpenClose

Dr. Pryzdial obtained his Ph.D. at the University of Toronto in biochemistry, working on complement, the plasma protein system that innately responds to pathogens. Postdoctoral training shifted gears to another plasma protein network, coagulation, at the University of Vermont, National Institutes of Health, Center of Excellence in Thrombosis. His primary appointment is now Senior Research Scientist with Canadian Blood Services. Dr. Pryzdial’s laboratory is at the University of British Columbia, Centre for Blood Research (http://cbr.ubc.ca/), where he recently completed two terms as Associate Director. He holds a UBC faculty position as Clinical Professor in the Department of Pathology and Laboratory Medicine. The work in his laboratory focuses on coagulation biochemistry and discovers mechanisms showing how this complicated cascade of proteins crosses over into virus infection and clot-busting, revealing new therapeutic targets. His lab’s studies are gratefully funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, and Canadian Blood Services.

 

Academic
OpenClose

Academic Background

  • BSc, University of Toronto, Biology, Chemistry Minor, Advanced Biochemistry, 1981
  • PhD, University of Toronto, Biochemistry, 1987
  • Postdoc, University of Vermont, 1990

Dr. Pryzdial obtained his Ph.D. at the University of Toronto in biochemistry, working on complement, the plasma protein system that innately responds to pathogens. Postdoctoral training shifted gears to another plasma protein network, coagulation, at the University of Vermont, National Institutes of Health, Center of Excellence in Thrombosis. His primary appointment is now Senior Research Scientist with Canadian Blood Services. Dr. Pryzdial’s laboratory is at the University of British Columbia, Centre for Blood Research (http://cbr.ubc.ca/), where he recently completed two terms as Associate Director. He holds a UBC faculty position as Clinical Professor in the Department of Pathology and Laboratory Medicine. The work in his laboratory focuses on coagulation biochemistry and discovers mechanisms showing how this complicated cascade of proteins crosses over into virus infection and clot-busting, revealing new therapeutic targets. His lab’s studies are gratefully funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, and Canadian Blood Services.

Awards and Recognition

Publications

https://pubmed.ncbi.nlm.nih.gov/?term=pryzdial%5BAuthor%5D&sort=date

Selected Publications

Research
OpenClose

Research Interest

There are two primary research interests in the Pryzdial Lab.

1) Virus-Induced Coagulopathy: Most (if not all) viruses that have a cell membrane sheathing, called an envelope, influence our clotting system. Mainly focusing on HIV, dengue virus and oral herpes virus, the Pryzdial team is seeking to find a common molecular basis to explain how these viruses trigger clotting and then design the first broad-spectrum antiviral agent to alleviate their respective pathologies.

2) Clot-Busting Enhancers: The favored clot-busting drug (rtPA) causes life-threatening bleeding far too often in patients with heart attacks, stroke, or deep vein thrombosis: approximately 6%. The Pryzdial Lab has discovered an overlooked mechanism that facilitates clot-busting without the need to administer rtPA, thus improving patient safety. Development of this new mode is underway using recombinant technology and preclinical animal models.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dr. Pryzdial coordinates PATH548K (Hemostasis Biochemistry), which is a small-class, highly interactive scenario, focusing on the students’ interests in hemostasis that strives to develop communication skills. He also periodically contributes to PATH502 (Current Topics in Pathology) and PATH521 (Introduction to the Pathogenesis of Human Disease).

Rosin, Miriam

Rosin, Miriam

BSc (Sask.), PhD (Tor.)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Founding Director, BC Oral Cancer Prevention Program | Founding Director, BC Oral Cancer Prevention Program

Affiliation(s): BCCA/BCCRC

Research and Scholarly Interests: Cancer, Informatics, Knowledge translation, Molecular Pathology and Cell Biology, Oral cancer prevention and management, Evidence-based risk assessment, Knowledge translation and community health, Big Data/AI initiatives as driving forces for oral cancer change

Clinical Interests:

Short Bio
OpenClose

Dr. Rosin is a translational scientist with a life-long passion of improving our capacity to prevent oral cancers. Her research has focused on the evolution of new, more comprehensive strategies to answer the ““who-, when-, and how-to-treat” trio of questions that underlie decision-making for individuals seen in clinic with premalignant lesions. She is PI on a unique Oral Cancer Prediction Longitudinal Study that has been following patients in BC with premalignant lesions, capturing multi-faceted data on disease progression. This effort has created a pipeline for research into the development of innovative molecular and adjunctive tools to facilitate clinical decision-making and remove barriers to oral cancer and precancer patient flow through the health system. A current large focus of her work is on the development of global strategies for integration of “Big Data” tools into oral cancer research frameworks to facilitate the evolution of new concepts and risk patterns that will guide the next generation of risk stratification processes.

Affiliations

 

Academic
OpenClose

Academic Background

  • PhD. (Cell Biology), University of Toronto, 1976
  • BSc. (Cell Biology), University of Saskatchewan, 1972

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Oral cancer prevention and management
  • Evidence-based risk assessment
  • Knowledge translation and community health
  • Big Data/AI initiatives as driving forces for oral cancer change
  • Translational research

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Tilley, Peter

Tilley, Peter

MD, FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): BCCH/BCCHRI

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Knowledge translation

Clinical Interests:

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • Fellow of the Royal College of Physicians and Surgeons of Canada, 1992
  • MD, University of British Columbia. 1986
  • BSc, (Hon) Biochemistry, Simon Fraser University. 1980

Awards and Recognition

Publications

Selected Publications

  • Tilley PA. Fox JD. Jayaraman GC. Preiksaitis JK. Maculopapular rash and tremor are associated with West Nile fever and neurological syndromes. Journal of Neurology, Neurosurgery & Psychiatry. 78(5):529-31, 2007 May.
  • Wong S, Burk VF, Pabbaraju K, Broukhanski GC, Fox JD, Louie T, Mah M, Broukhanski G, Tilley PAG. Use of Sequence Based Typing for Investigation of Nosocomial Legionellosis in a Low Prevalence Population. Journal of Medical Microbiology. 55(Pt 12):1707-10, 2006 Dec..
  • Tilley PAG, JD Fox, GC Jayaraman, JK Preiksaitis. Nucleic Acid Testing for West Nile Virus RNA in Plasma Enhances the Diagnosis of Acute Infection in Symptomatic Patients. J Infect Dis 2006 193(10):1361-4.
  • Knorr L, Fox JD, Tilley P, Ahmed-Bentley J. Evaluation of Real-Time PCR for diagnosis of Bordetella pertussis. Biochemical Central BMC Infectious Diseases 2006. 6(62);1-12.
  • Cameron C, J Reeves, N Antonishyn, P Tilley, T Alport, B Eurich, D Towns, D Lane, J Saldhana. West Nile Virus in Canadian Blood Donors. Transfusion 2005. 45(4):487-91.
  • Gorsche R, P Tilley. The rash of West Nile virus infection. CMAJ 2005. 172(11):1440.
  • Melito PL, D.L. Woodward, J. Munro, J. Walsh, R. Foster, P. Tilley, A. Paccagnella, J. Isaac-Renton, J. Ismail. A Novel Shigella dysenteriae Serovar Isolated in Canada. J of Clin Microbiol 2005 43(2):740-4.
  • Tilley,P.A.; Zachary,G.A.; Walle,R.; Schnee,P.F. West Nile virus detection and commercial assays. Emerging Infectious Diseases. 2005. 11(7):1154-5,
  • Tilley,P.A.; Walle,R.; Chow,A.; Jayaraman,G.C.; Fonseca,K.; Drebot,M.A.; Preiksaitis,J.; Fox,J. Clinical utility of commercial enzyme immunoassays during the inaugural season of West Nile virus activity, Alberta, Canada. J Clin Microbiol. 2005. 43(9):4691-5.
  • Fonseca K., Prince G.D., Bratvold J., Fox J.D., Pybus M., Preiksaitis J.K., Tilley P. West Nile virus and conjunctival exposure. Emerging Infectious Diseases 2005. 11(10) 1648-9.
Research
OpenClose

Research Interest

Research Areas

Timely and accurate diagnosis of infectious agents is of the utmost importance in treating pediatric patients. I am interested in exploring how new technologies can be applied to improve the diagnosis of infectious disease and enable the best possible care of children.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Vallance, Hilary

Vallance, Hilary

MD, FRCPC, FCCMG (Biochemical Genetics)

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): BCCH/BCCHRI

Research and Scholarly Interests: Endocrinology, Metabolism & Nutrition, Genetics genomics proteomics and related approaches, Scholarship of Teaching of Education Research

Clinical Interests:

Short Bio
OpenClose

Dr. Hilary Vallance is a Medical Biochemist / Biochemical Geneticist at BC Children’s Hospital who obtained her MD from the University of British Columbia (UBC). She completed a residency in Medical Biochemistry at UBC followed by fellowship training in Biochemical Genetics. She is the Director of the BC Newborn Screening Program. Her research contributions have been in the area of inborn errors of metabolism, maternal and infant B12 deficiency and newborn screening for treatable conditions.

 

Academic
OpenClose

Academic Background

  • FCCMG, University of British Columbia, Biochemical Genetics. 1996
  • FRCPC, University of British Columbia, Medical Biochemistry. 1993
  • MD, University of British Columbia, Medicine. 1987
  • Cell Biology, University of British Columbia. 1983

Awards and Recognition

  • Excellence in Mentoring award, Dept of Pathology and Laboratory Medicine – 2018
  • Dr. Parminder Singh Award, British Columbia Pediatric Society – 2011

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Prevalence and natural history of a common variant in the Carnitine Palmitoyl transferase Ia gene in BC and Northern aboriginal populations.
  • Maternal and Infant B12 deficiency.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

  • Teaching and Learning: She has served on the CCMG Board of Directors, Chair – CCMG Exam advisory committee (2017-2022) and membership on the following: Accreditation, Biochemical Genetics and Training committees.

Carter, Cedric

Carter, Cedric

MB, BS, MRC, FRCPC

Academic Rank(s): Associate Professor Emeritus, Pathology and Laboratory Medicine, UBC

Affiliation(s): BC Cancer Research Centre

Research and Scholarly Interests: Blood Research, Development and Demonstration of Clinical Efficacy of Low Molecular Weight Heparin Fractions, Investigation of a New Antithrombin-III Variant with Discrepant Functional to Immuno ATIII Levels, Development of Laboratory Markers to Detect Hypercoagulable States, Diagnostic Application of Platelet Activation Dependent Antibodies

Clinical Interests:

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • BS, St. Thomas Hospital Medical School, Surgery
  • MB, University of London, Medicine. 1969
  • FRCP(C), Internal Medicine. 1976
  • FRCP(C), Haematology. 1976
  • FRCP(London), Internal Medicine. 1991

Awards and Recognition

Publications

Carter, Cedric PUBMED

Selected Publications

Research
OpenClose

Research Interest

  • Blood research, blood clotting; thrombosis
  • The development and demonstration of clinical efficacy of low molecular weight heparin fractions
  • Investigation of a new antithrombin-III variant with discrepant functional to immuno ATIII levels
  • Development of laboratory markers to detect hypercoagulable states
  • Diagnostic application of platelet activation dependent antibodies

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Côté, Hélène

Côté, Hélène

BSc (Laval University ), PhD (University of British Columbia)

Academic Rank(s): Professor, UBC, Department of Pathology and Laboratory Medicine | Investigator, Centre for Blood Research, Member, Centre for Blood Research, LSC | Vice Chair of Scientific Education, Dept of Pathology & Laboratory Medicine

Affiliation(s): UBC Hospital, Centre for Blood Research, Women’s Health Research Institute

Research and Scholarly Interests: HIV, chronic/latent viruses, aging, markers of biological aging, women’s health, antiretroviral drug toxicity, HIV pregnancy, cohort studies, community-engaged research

Short Bio
OpenClose

Dr. Côté’s https://cotelab.pathology.ubc.ca/
Dr. Côté is a Professor in the Department of Pathology and Laboratory Medicine (PALM) at the University of British Columbia. She currently serves as Vice-Chair of Scientific Education in PALM and Director/Graduate Advisor for the PALM Graduate Program. Dr. Côté is also an Associate member of the Women’s Health Research Institute, an investigator of the UBC Centre for Blood Research, and a member of the Edwin S.H. Leong Healthy Aging Program at UBC.

Following post-doctoral training at the University of Washington she worked at the BC Centre for Excellence in HIV/AIDS where she studied HIV antiretroviral drug toxicity. She then joined the Department of Pathology and Laboratory Medicine, supported by a Michael Smith Foundation for Health Research Scholar Award, and moved to the UBC campus where her research program has focused on mitochondrial aging and immune cell aging, in persons living with HIV and other chronic/latent viruses, as well as in children exposed antenatally to antiretroviral agents. She has been the lead Principal Investigator on the CARMA cohort study from 2008-2018, and currently co-leads the British Columbia CARMA-CHIWOS Collaboration study, a holistic Cell-to-Society study of healthy aging among women living with HIV https://hivhearme.ca/studies/.

 

Academic
OpenClose

Academic Background

  • BSc, Biochemistry, Laval University. 1987
  • PhD, Biochemistry, University of British Columbia. 1993
  • Post-doctoral Fellow, Biochemistry, University of British Columbia. 1994
  • Post-doctoral Fellow, Biochemistry, University of Washington. 1995-1998
  • Research Associate II, British Columbia Centre for Excellence in HIV/AIDS. 1998-2004
  • Research Scholar B.C. Foundation for Health Research (MSFHR)/St.Paul’s Hospital Foundation Joint Scholarship. 1999-2003
  • Michael Smith Foundation for Health Research Scholar. 2004-2009
  • CIHR New Investigator. 2007-2012

Awards and Recognition

Publications

Full list of publications may be found here.

Research
OpenClose

Research Interest

  • HIV infection, antiretroviral therapy and aging
  • Drug mitochondrial toxicity
  • Markers of biological aging
  • Blood Research
  • Infectious Diseases

Dr. Cote’s research concentrates on the mitochondrial toxicity of drugs, primarily antiretroviral drugs used in HIV therapy. HIV combination therapy has significantly decreased mortality in the HIV infected population. However, treatment is life-long and as HIV infected individuals survive longer, the toxicity of the drugs and the serious side effects associated can cause of morbidity, non-adherence to prescribed therapy and mortality. HIV drugs can increase mitochondrial DNA (mtDNA) depletion/mutation/deletion through pressure on polymerase gamma, the enzyme responsible for mtDNA replication. In addition, some HIV drugs can inhibit telomerase, the enzyme complex elongating telomeric DNA. MtDNA damage and telomere shortening have been associated with diseases and aging.

Current Projects In My Lab Include

  1. Antiretroviral mitochondrial toxicity and telomere attrition in infants born to HIV-infected mothers.
  2. Antiretroviral mitochondrial toxicity and telomere attrition in HIV-infected adults and children, as well as during pregnancy.These two projects study the toxicity of the drug in pregnant HIV infected women and their infants, two populations who are particularly vulnerable to drug-related toxicity. The longitudinal effect of HIV therapy on mtDNA quantity and telomere length in mother and child and the potential effect on mtDNA quality in the children are being investigated.
  3. Mitochondrial toxicity in HIV/hepatitis C virus co-infection antiviral therapy. The HIV/HCV coinfected population is also at higher risk of drug-related adverse events as liver damage cause by both viruses and the drugs add up. We are studying the effect of antiviral drugs on the liver mitochondria in patients undergoing HCV therapy, as well as the effect of therapy on drug metabolism by the liver.

 

Other lab interests:

  1. Mitochondrial toxicity of non-HIV drugs such as statins
  2. Acquired mitochondrial disease-like syndromes
Teaching
OpenClose

Teaching Interest

Granville, David

Granville, David

PhD, FAHA

Academic Rank(s): Professor, Faculty of Medicine at The University of British Columbia and Co-Founder and CSO, viDA Therapeutics

Affiliation(s): ICORD and HLI

Research and Scholarly Interests: Translational research, drug discovery, proteases, extracellular matrix, aging, dermatology, autoimmune disease, inflammation, vascular dysfunction, wound healing

Clinical Interests: Bridging research and clinical practice, skin health and disease mechanisms, cardiovascular and pulmonary health, development of novel therapeutics, understanding tissue injury and healing

Short Bio
OpenClose

Dr. David Granville is a Professor in the UBC Faculty of Medicine. He was previously the Associate Dean Research, UBC Faculty of Medicine and Executive Director of the Vancouver Coastal Health Research Institute, the largest hospital-based research institute in Western Canada. He is currently a Principal Investigator at the ICORD Centre, the UBC Centre for Heart Lung Innovation and the Director of the Wound Healing and Chronic Disease Research Lab, ICORD, UBC.

Dr. Granville previously worked at QLT, Inc. (1994-2001) where his R&D studies supported the approval of Visudyne® to be used as the first treatment for macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history.

Dr. Granville’s research is referred to on the drug label for Visudyne®. In 2001, Dr. Granville moved to Scripps where he discovered a novel therapeutic target for attenuating ischemic heart injury related to myocardial infarction and transplantation, which led to the formation of Radical Therapeutix (San Diego, CA). He was recruited back to UBC as an Assistant Professor, Canada Research Chair and MSFHR Scholar to work at the UBC Centre for Heart Lung Innovation (2003-2016).

In 2016 he relocated to the ICORD Centre/VCHRI/UBC. Dr. Granville has received numerous awards including a Michael Smith Foundation for Health Research Scholar Award, Canada Research Chair, Canada Top 40 Under 40 Award, Business in Vancouver Top Forty Under 40, Canadian Association of Pathology Scientist Award, UBC Outstanding Young Alumnus Award, SFU Academic Alumnus Award, runner-up for the American Heart Association Louis and Arnold Katz Basic Science Prize and recent recipient of the CIHR Institute of Aging Prize for Excellence in Research in 2022. He is also a Scholar of the Royal Society of Canada and a Fellow of the American Heart Association.

His current research is focused on mechanisms of tissue injury, inflammation and repair and how aging and dysregulated inflammation affect such processes in the context of identifying new therapeutic targets for the treatment of age-related and/or chronic diseases. His recent research has led to the formation of the UBC-spin-off company, viDA Therapeutics of which he is a co-Founder and Chief Scientific Officer.

 

Academic
OpenClose

Academic Background

  • PDF, The Scripps Research Institute, Molecular and Experimental Medicine. 2003
  • PhD, The University of British Columbia, Pathology and Laboratory Medicine. 2001
  • BSc, Simon Fraser University, Biological Sciences. 1994

Awards and Recognition

Publications

PUBMED

Research
OpenClose

Research Interest

Over the past 20 years, Dr. Granville’s research program has focused on identifying mechanisms that underlie tissue injury and therapeutic targets that can be exploited to reduce injury and/or promote healing. Dr. Granville’s research team is investigating a family of cell-secreted proteases known as granzymes (granule-secreted enzymes) and their role in aging and chronic inflammation. At UBC, Dr. Granville’s laboratory has been a significant contributor to challenging the existing dogma that granzymes (granule-secreted enzymes) function solely as an intracellular mediator of lymphocyte-induced targeted cell death. His team was first to demonstrate a novel extracellular role for granzyme B in a disease model. Dr. Granville’s group has since identified that granzymes are elevated and contribute to the pathogenesis of conditions associated with impaired healing and inflammation, including skin injuries, autoimmune skin diseases, in addition to cardiovascular and pulmonary diseases. In order to study granzymes in a diverse set of indications, Dr. Granville collaborates with a network of expert clinical and scientific collaborators.

Dr. Granville is currently translating his discoveries into the development and commercialization of novel, first-in-class therapeutics. Dr. Granville’s team is expanding on their discoveries in tissue injury, inflammation, and repair, and applying their expertise to vessel wall injury, aging, and chronic diseases. Dr. Granville also continues to lead an established research program examining the role of granzymes in cardiovascular and pulmonary diseases. Dr. Granville’s team is currently one of few groups in the world conducting translational research and therapeutics targeting granzymes in disesase.

Current Projects In My Lab Include

Although his laboratory is quite full at the moment, Dr. Granville is always on the lookout for talented, energetic and bright graduate students and post-doctoral fellows to join his team if funding is available. Please contact Dr. Granville with inquiries.

Teaching
OpenClose

Teaching Interest

Kizhakkedathu, Jayachandran

Kizhakkedathu, Jayachandran

PhD

Academic Rank(s): Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): Centre for Blood Research, LSCSchool of Biomedical EngineeringChemistry

Research and Scholarly Interests: Biomaterials, Blood research

Clinical Interests:

Short Bio
OpenClose

Dr. Jay Kizhakkedathu is a Professor and Tier 1 Canada Research Chair in the Department of Pathology and Laboratory Medicine, a Principal Investigator at the Centre for Blood Research (CBR) and an Associate Member with the Department of Chemistry, The School of Biomedical Engineering at the University of British Columbia (UBC), Vancouver, Canada. Dr. Kizhakkedathu is leading a cutting-edge translational research program to innovate materials and therapeutics that can treat and prevent thrombosis, bleeding, immunothrombosis and infection, immunological rejection of organs and cells, and protection of tissues and organs in inflammatory conditions.

Dr. Kizhakkedathu’s research has been published in both fundamental science and clinical journals including the top journals in biomaterials, biotechnology, materials, translation medicine and hematology (~235): Science Translational Medicine, Nature Materials, Nature Biotechnology, Nature Biomedical Engineering, Nature Communications, Blood, Journal of the American Chemical Society, Biomaterials, ACS Nano, ACS Central Science among many others, and several patents (~35) which form the foundation of a few companies.

Dr. Kizhakkedathu has received numerous other awards and recognitions including the Canada Research Chair Tier 1 in Immunomodulating Materials and Immunotherapy, Distinguished Achievement Award in Excellence in Basic Science Research from Faculty of Medicine in 2022, named as a Fellow Biomaterials Science and Engineering (FBSE) (2020) by the World Biomaterials Congress, the UBC Killam Research Prize in 2017, and the Department of Pathology and Laboratory Medicine Excellence in Research and Discovery Award in 2011. He was also recognized as a Michael Smith Foundation for Health Research Scholar (MSFHR) in 2011 and was honoured with the Canadian Institutes of Health Research (CIHR) New Investigator Award in 2005.

 

Academic
OpenClose

Academic Background

Dr. Jay Kizhakkedathu is a Professor and Tier 1 Canada Research Chair in the Department of Pathology and Laboratory Medicine, a Principal Investigator at the Centre for Blood Research (CBR) and an Associate Member with the Department of Chemistry, The School of Biomedical Engineering at the University of British Columbia (UBC), Vancouver, Canada. Dr. Kizhakkedathu is leading a cutting-edge translational research program to innovate materials and therapeutics that can treat and prevent thrombosis, bleeding, immunothrombosis and infection, immunological rejection of organs and cells, and protection of tissues and organs in inflammatory conditions.

Dr. Kizhakkedathu has received numerous other awards and recognitions including the Canada Research Chair Tier 1 in Immunomodulating Materials and Immunotherapy, Distinguished Achievement Award in Excellence in Basic Science Research from Faculty of Medicine in 2022, named as a Fellow Biomaterials Science and Engineering (FBSE) (2020) by the World Biomaterials Congress, the UBC Killam Research Prize in 2017, and the Department of Pathology and Laboratory Medicine Excellence in Research and Discovery Award in 2011. He was also recognized as a Michael Smith Foundation for Health Research Scholar (MSFHR) in 2011 and was honoured with the Canadian Institutes of Health Research (CIHR) New Investigator Award in2005.

Dr. Kizhakkedathu’s research has been published in both fundamental science and clinical journals including the top journals in biomaterials, biotechnology, materials, translation medicine and hematology (~235): Science Translational Medicine, Nature Materials, Nature Biotechnology, Nature Biomedical Engineering, Nature Communications, Blood, Journal of the American Chemical Society, Biomaterials, ACS Nano, ACS Central Science among many others, and several patents (~35) which form the foundation of a few companies.

Full details of Dr. Kizhakkedathu’s publications can be found on Google Scholar: https://scholar.google.ca/citations?user=zL7GeOwAAAAJ&hl=en.

Awards and Recognition

  • UBC Faculty of Medicine ‘ Distinguished Achievement Award’. 2013
  • MSFHR Career Scholar. 2011
  • Department of Pathology and Laboratory Medicine ‘Excellence in Research and Discovery Award’. 2011
  • CIHR New Investigator. 2005

Publications

Selected Publications

  • Kalathottukaren MT, Abraham L, Kapopara PR, Benjamin FL Lai BFL, Shenoi RA, Rosell FI, Conway EM, Pryzdial ELG, Morrissey JH, Haynes CA, Kizhakkedathu JN. ( 2016)  Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA. Blood 2016 :blood-2016-10-747915; doi: https://doi.org/10.1182/blood-2016-10-747915
  • Yu K, Lo JC, Yan M, Yang X, Brooks DE, Hancock RE, Lange D, Kizhakkedathu JN. (2016) Anti-adhesive antimicrobial peptide coating prevents catheter associated infection in a mouse urinary infection model. Biomaterials. 2017 Feb;116:69-81.
  • Du C, Mendelson AA, Guan Q, Dairi G, Chafeeva I, da Roza G, Kizhakkedathu JN. (2016) Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis. J Transl Med. 14(1):338.
  • Loy C, Meghezi S, Lévesque L, Pezzoli D, Kumra H, Reinhardt D, Kizhakkedathu JN, Mantovani D. (2016) A planar model of the vessel wall from cellularized-collagen scaffolds: focus on cell-matrix interactions in mono-, bi- and tri-culture models. Biomater Sci. 20;5(1):153-162.
  • Brockman KS, Kizhakkedathu JN, Santerre JP. (2016). Hemocompatibility studies on a degradable polar hydrophobic ionic polyurethane (D-PHI). Acta Biomater. 2016 Nov 3. pii: S1742-7061(16)30592-X. doi: 10.1016/j.actbio.2016.11.005.
  • Hamilton JL, Ul-Haq MI, Creagh AL, Haynes CA, Kizhakkedathu JN. (2016) Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density. Macromol Biosci. doi: 10.1002/mabi.201600244.
  • Shenoi RA, Abbina S, Kizhakkedathu JN. (2016) In Vivo Biological Evaluation of High Molecular Weight Multifunctional Acid-Degradable Polymeric Drug Carriers with Structurally Different Ketals. Biomacromolecules. 2016 17(11):3683-3693.
  • Li S, Constantinescu I, Guan Q, Kalathottukaren MT, Brooks DE, Nguan CY, Kizhakkedathu JN, Du C. Advantages of replacing hydroxyethyl starch in University of Wisconsin solution with hyperbranched polyglycerol for cold kidney perfusion. J Surg Res. 205(1):59-69.
  • Yang X, Li N, Constantinesco I, Yu K, Kizhakkedathu JN, Brooks DE. (2016) Choline phosphate functionalized cellulose membrane: A potential hemostatic dressing based on a unique bioadhesion mechanism. Acta Biomater. 40:212-25.
  • Hamilton JL, Imran Ul-Haq M, Abbina S, Kalathottukaren MT, Lai BF, Hatef A, Unniappan S, Kizhakkedathu JN. (2016)  In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator. Biomaterials. 102:58-71.
  • Lai ZW, Weisser J, Nilse L, Costa F, Keller E, Tholen M, Kizhakkedathu JN, Biniossek M, Bronsert P, Schilling O. (2016) Formalin-Fixed, Paraffin-Embedded Tissues (FFPE) as a Robust Source for the Profiling of Native and Protease-Generated Protein Amino Termini. Mol Cell Proteomics. 15(6):2203-13.
  • Wen J, Weinhart M, Lai B, Kizhakkedathu JN, Brooks DE.  Reversible hemostatic properties of sulfabetaine/quaternary ammonium modified hyperbranched polyglycerol. Biomaterials 86, 42-55.
  • Moradi S, Hadjesfandiari N, Toosi SF, Kizhakkedathu JN*, Hatzikiriakos SG*. (2016) Effect of Extreme Wettability on Platelet Adhesion on Metallic Implants: From Superhydrophilicity to Superhydrophobicity. ACS Appl Mater Interfaces. 8(27):17631-41. (*equal senior authors)
  • Tholen S, Wolf C, Mayer B, Knopf JD, Löffek S, Qian Y, Kizhakkedathu JN, Biniossek ML, Franzke CW, Schilling O. (2016) Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations. Journal of proteome research 15 (5), 1402-1417.
  • Leung VL, Kizhakkedathu JN. (2016) The mechanism and modulation of complement activation on polymer grafted cells. Acta biomaterialia 31, 252-263.
  • Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever D, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O. (2016). Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Molecular oncology 10 (1), 40-58.
  • Wong NK, Misri R, Shenoi RA, Chafeeva I, Kizhakkedathu JN*, Khan MK*. (2015) Design considerations for developing hyperbranched polyglycerol nanoparticles as systemic drug carriers. Journal of Biomedical Nanotechnology J Biomed Nanotechnol. 12(5):1089-100. (*equal senior authors).
  • Yu K, Creagh AL,  Haynes CA, Kizhakkedathu JN. (2016) Modulation of Multivalent Protein Binding on Surfaces by Glycopolymer Brush Chemistry. Macro-Glycoligands: Methods and Protocols, 183-193
  • Yu K, Lo JC, Mei Y, Haney EF, Siren E, Kalathottukaren MT, Hancock RE, Lange D, Kizhakkedathu JN. (2015) Toward Infection-Resistant Surfaces: Achieving High Antimicrobial Peptide Potency by Modulating the Functionality of Polymer Brush and Peptide. ACS Appl Mater Interfaces. 7(51):28591-605.
  • Narain R, Wang Y, Ahmed M, Lai BF, Kizhakkedathu JN. (2015). Blood Components Interactions to Ionic and Nonionic Glyconanogels. Biomacromolecules. 16(9):2990-7.
  • Yu K, Lai BFL, Gani J.; Mikut R, Hilpert K, Kizhakkedathu JN. (2015)Interaction of Blood Components with Natural Cathelicidins and Artificial Short Antimicrobial Peptides. Biomaterials 69, 201-211.
  • Schlage P, Kockmann T, Sabino F, Kizhakkedathu JN, Auf dem Keller U. (2015) Matrix Metalloproteinase 10 Degradomics in Keratinocytes and Epidermal Tissue Identifies Bioactive Substrates With Pleiotropic Functions. Mol Cell Proteomics. 14(12):3234-46.
  • Shenoi RA, Chafeeva I, Lai, BFL, Horte S, Kizhakkedathu JN. (2015) Bioreducible Hyperbranched Polyglycerols with Disulfide Linkages: Synthesis and Biocompatibility Evaluation. Journal of Polymer Science: Part A Polymer Chemistry  53 (18), 2104-2115.
  • Yang X,   Li N, Kizhakkedathu JN,  Brooks DE. ( 2015) Choline Phosphate Functionalized Cellulose Membrane Developed as Potential Hemostasis Dressing Based on a Unique Bioadhesion Mechanism. International Journal of Bioscience, Biochemistry and Bioinformatics 5 (4), 211.
  • Schlage P, Kockmann T, Kizhakkedathu JN, auf dem Keller U. (2015) Monitoring matrix metalloproteinase activity at the epidermal-dermal interface by SILAC-iTRAQ-TAILS. Proteomics. 15 (14), 2491-2502.  
  • Kwan D, Constantinescu I, Chapanian R, Higgins, M, Koetzler M, Samain E, Boraston AB, Kizhakkedathu, JN; Withers, S. (2015) Towards efficient enzymes for the generation of universal blood through structure-guided directed evolution. J. Am. Chem. Soc. 137 (17), 5695-5705.
  • Melzak KA, Yu K, Bo D, Kizhakkedathu JN*, Toca-Herrera JL* (2015). Chain Length and Grafting Density Dependent Enhancement in the Hydrolysis of Ester-Linked Polymer Brushes. Langmuir. 16; 31(23):6463-70. (*equal senior authors).
  • Misri R, Wong NK, Shenoi RA, Lum CM, Chafeeva I, Toth K, Rustum Y, Kizhakkedathu JN*, Khan MK*. (2015) Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics. Nanomedicine-Nanotechnology Biology and Medicine. 11 (7), 1785-1795 (*equal senior authors)
  • Hamilton JL, Kizhakkedathu JN. Polymeric nanocarriers for the treatment of systemic iron overload. Molecular and Cellular Therapies. 2015, 3:3DOI: 10.1186/s40591-015-0039-1.
  • Gao S, Guan Q, Chafeeva I, Brooks DE, Nguan CY, Kizhakkedathu JN*, Du C.* Hyperbranched polyglycerol as a colloid in cold organ preservation solutions. PLoS One. 2015 Feb 23;10(2):e0116595. (*equal senior authors)
  • Kumar P, Shenoi RA, Lai BF, Nguyen M, Kizhakkedathu JN,* Straus SK.*Conjugation of Aurein 2.2 to HPG Yields an Antimicrobial with Better Properties. Biomacromolecules. 2015 Mar 9;16(3):913-23 (*equal senior authors)
  • Godoy-Gallardo M, Mas-Moruno C, Yu K, Manero JM, Gil FJ, Kizhakkedathu JN, Rodriguez D.Antibacterial properties of hLf1-11 peptide onto titanium surfaces: a comparison study between silanization and surface initiated polymerization. 2015 Feb 9;16(2):483-96.
  • Sabino F, Hermes O, Egli FE, Kockmann T, Schlage P, Croizat P, Kizhakkedathu JN, Smola H, auf dem Keller U. In vivo assessment of protease dynamics in cutaneous wound healing by degradomics analysis of porcine wound exudates. Mol Cell Proteomics. 2015 Feb;14(2):354-70.
  • Stukas S, Robert J, Lee M, Kulic I, Carr M, Tourigny K, Fan J, Namjoshi D, Lemke K, DeValle N, Chan J, Wilson T, Wilkinson A, Chapanian R, Kizhakkedathu JN, Cirrito JR, Oda MN, Wellington CL. Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J Am Heart Assoc. 2014 Nov 12;3(6):e001156.
  • Shenoi RA, Kalathottukaren MT, Travers RJ, Lai BF, Creagh AL, Lange D, Yu K, Weinhart M, Chew BH, Du C, Brooks DE, Carter CJ, Morrissey JH, Haynes CA, Kizhakkedathu JN. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Science Transl Med. 2014 Oct 29;6(260):260ra150
Research
OpenClose

Research Interest

Dr. Kizhakkedathu is leading a translational research program is to innovate materials and therapeutics to treat and prevent immunothrombosis, immunological rejection of organs and cells, and protection of tissues and organs in inflammatory conditions and infection resistant devices. Dr. Kizhakkedathu is recognized in the development of novel polymers for cell-surface engineering, and as therapeutics, antibiofilm coatings and proteomic tools. Kizhakkedathu’s research is based on tailoring molecular level interactions of synthetic polymers with biological systems to design novel biomaterials in a translational setting. Dr. Kizhakkedathu takes an integrative, interdisciplinary approach combining an understanding of the pathophysiology of diseases and advanced polymer synthesis with well‐designed biological assays and animal models to discover therapeutics, and technologies for biomedical and clinical use.

(We are always looking for talented graduate students and postdoctoral fellows for our interdisciplinary research program. Please send your updated CV along with a cover letter).

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Luo, Honglin

Luo, Honglin

MS, MD (Chongqing)

Academic Rank(s): Professor, Department of Pathology & Laboratory Medicine, Faculty of Medicine, UBC |

Affiliation(s): Centre for Heart Lung Innovation at St. Paul’s Hospital

Research and Scholarly Interests: Myocarditis, RNA viruses, viral pathogenesis, oncolytic virus, virotherapy, protein/organelle quality control, amyotrophic lateral sclerosis, lung and breast cancer

Clinical Interests: research in viral infections, cardiovascular diseases, and the development of new therapeutic strategies using viruses, particularly in the context of cancer treatment and cardiovascular health

Short Bio
OpenClose

Dr. Luo received her MD and MSc in Biomedical Engineering in China. She then pursued a postdoctoral training in Cardiovascular research with a focus on signal transduction at the University of Washington. Dr. Luo is currently a full Professor at the University of British Columbia, Canada. The focus of her research program is to understand and engineer viral mechanisms to develop new therapies. Dr. Luo has published 120 peer-reviewed papers (H-index=42 and i10-index=81 according to Google Scholar). The ongoing research projects include: (1) Understanding molecular mechanisms of impaired cardiac function in enteroviral myocarditis; (2) Determining the possible role of enteroviral infection in the development of amyotrophic lateral sclerosis (ALS); and (3) Developing coxsackievirus B3 (CVB3) as an oncolytis virus for lung cancer treatment.

Academic
OpenClose

Academic Background

  • Postdoctoral Fellow – University of Washington, Seattle. 2000
  • MSc – Sichuan University (Former West China University of Medical Sciences), Chengdu, China. 1989
  • MD – Chongqing Medical University, Chongqing, China. 1986

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

The focus of Dr. Luo’s research program is to define the molecular and pathogenetic determinants of virus-host interactions in enterovirus-induced cardiac and neurodegenerative diseases. The ongoing research projects include:

  • Understanding molecular mechanisms of impaired cardiac function in enteroviral myocarditis. This research focuses on the protein quality control system, which includes molecular chaperones and protein degradation pathways (i.e., the ubiquitin-proteasome system and autophagy) with the long-term goal to design effective molecular therapies for this disease;
  • Determining the possible role of enteroviral infection in the development of amyotrophic lateral sclerosis (ALS). Dr. Luo’s laboratory recently made an exciting discovery that enteroviral infection results in the hallmark molecular and pathological features of ALS. The current project aims to establish and understand the contribution of enteroviral infection in the pathogenesis of ALS and to test whether application of anti-enterovirus drugs can lessen the progression of ALS; and
  • Developing coxsackievirus B3 (CVB3) as an oncolytis virus for lung cancer treatment. Using cell and mouse models, Dr. Luo’s group recently found that CVB3 is an extremely potent anti-tumor virus, destroying various types of lung cancer cells, with limited effects on normal cells. The present research is to genetically engineer CVB3 to further enhance its safety and anti-tumor potency for the treatment of lung cancer.
    • Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dr. Luo is actively involved in graduate-level teaching.

Nielsen, Torsten

Nielsen, Torsten

MD/PhD FRCPC

Academic Rank(s): Professor, Department of Pathology & Laboratory Medicine, Faculty of Medicine, UBC | Director, UBC MD/PhD Program

Affiliation(s): Vancouver General Hospital and the BC Cancer Agency

Research and Scholarly Interests: Sarcoma, breast cancer, histopathology, molecular diagnostics

Clinical Interests: Musculoskeletal pathology, particularly in the diagnosis of connective tissue neoplasms and sarcomas

Short Bio
OpenClose

Professor Torsten Nielsen completed the MD/PhD program at McGill followed by a residency in Anatomical Pathology at UBC, before taking up a position as a clinician-scientist. He combines work as a musculoskeletal subspecialty pathologist with active grant-funded research programs in breast cancer and sarcomas, the common themes of which are the translation of genomic discoveries into clinically-practical new diagnostics and treatments. Among his accomplishments in sarcoma research are the development of novel diagnostic tests for synovial sarcoma, gastrointestinal stromal tumor and liposarcomas, and the identification of driver events leading to new treatments for tenosynovial giant cell tumor and epithelioid sarcoma. In breast cancer Dr. Nielsen pioneered intrinsic subtyping tests including the FDA-cleared PAM50 (Prosigna) assay, and has taken a lead role in international efforts to standardize Ki67 and immune biomarkers for implementation in hospital pathology laboratories. He is active with clinical trials groups and is the Director of UBC’s combined MD/PhD program, training a new generation of clinician-scientists.

Academic
OpenClose

Academic Background

  • MD/PhD, McGill University. 1997
  • PhD, Experimental Medicine, McGill University. 1996
  • BSc, Biochemistry (1st class honours) University of British Columbia. 1991

Awards and Recognition

Publications

 

Publications

Research
OpenClose

Research Interest

  • Translational research in breast cancer – developing clinically-practical predictive biomarkers using tissue microarray and Nanostring technology
  • Molecular oncology of sarcomas afflicting the AYA (adolescent and young adult) population – synovial sarcoma, myxoid liposarcoma, epithelioid sarcoma and related cancers
  • Correlative science support for clinical trials in breast cancer and sarcoma, in association with the Canadian Cancer Trials Group

Current Projects In My Lab Include

Dr. Nielsen’s active projects are listed at: http://www.gpecdata.med.ubc.ca/torsten/ActiveResearch.html 

Teaching
OpenClose

Teaching Interest

Director, UBC MD/PhD program: https://mdprogram.med.ubc.ca/mdphd/directors-message/

Blondel-Hill, Edith

Blondel-Hill, Edith

MD, FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Medical Microbiology/Infectious Diseases Specialist, Interior Health Microbiology Consultant, Kelowna General Hospital | Medical Director, Do Bugs Need Drugs? Program

Affiliation(s): Interior Health Authority

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Microbiology, Microscopy, Antibiotics, Applied Microbiology, Antibiotic Resistance

Clinical Interests:

Short Bio
OpenClose

Dr. Edith Blondel-Hill trained at the University of Alberta, Edmonton, Alberta, Canada and received specialty training in internal medicine, infectious diseases and medical microbiology. She started her career at the Royal Alexandra Hospital in Edmonton as an infectious diseases consultant and medical microbiologist and moved to Dynacare Kasper Medical Laboratories in 1997. She moved to British Columbia in 2003 where she worked as a microbiology consultant at BC Children’s Hospital in Vancouver until 2008. She is currently the microbiology consultant for Interior Health and is located at the Kelowna General Hospital in Kelowna, British Columbia. She has a long interest in antimicrobial utilization, chairing various antimicrobial advisory committees in Alberta and British Columbia as well as being involved in guideline and policy development for antibiotic use and prescribing. She is co-author of the Bugs and Drugs – Antimicrobial Reference Book and the medical director of the Do Bugs Need Drugs? program, an educational program to address antimicrobial resistance. Her major interests include mechanisms of resistance and susceptibility testing.

Do Bugs Need Drugs?
The Do Bugs Need Drugs? program continues to be an important health initiative in BC. Since its inception, 25000 grade 2 children, 5000 children in day care, and 6000 health care professionals have received educational components of the Do Bugs Need Drugs? program, the majority of phy­sicians’ offices have received materials, and most British Columbians have come into contact with the media campaigns.

The upward trend in the use of antibiotics seen from 2003 to 2005 has been arrested and encouraging de­clines in pediatric use are observed. BC physicians are more likely than Canadian physicians overall to prescribe no antibiotic for several common respiratory tract infections or to use first-line antibiotics if doing so.

Nevertheless, due to the growing resistance of bacteria to macrolides and fluoroquinolones, decreasing their use continues to be a main objective of the program. In this issue of BCMJ you will find an order form for program materials. Information for physicians is also posted at www.dobugsneeddrugs.org.

 

Academic
OpenClose

Academic Background

  • MD (Honours), University of Alberta. 1986
  • BSc, University of Alberta. 1982

Awards and Recognition

Publications

Dr. Edith Blondel-Hill PUBMED

Selected Publications

Research
OpenClose

Research Interest

Microbiology, Microscopy, Antibiotics, Applied Microbiology, Antibiotic Resistance

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Bondy, Greg

Portrait photo of Greg  Bondy

Bondy, Greg

MD, FRCPC

Academic Rank(s): Clinical Associate Professor, Pathology and Laboratory Medicine, UBC | Researcher, BC Centre for Excellence in HIV/AIDS

Affiliation(s): St. Paul’s Hospital, BC Centre for Excellence in HIV

Research and Scholarly Interests: Cardiovascular and Pulmonary, Endocrinology, Metabolism & Nutrition, Infectious Diseases and Immunology Microbiology, HIV/AIDS

Clinical Interests:

Short Bio
OpenClose

Dr. Greg Bondy works as a Specialist in the John Reudy Immunodeficiency Clinic (IDC), a collaboration between the BC Centre for Excellence and Providence Health Care.

 

Academic
OpenClose

Academic Background

  • MD University of Toronto. 1981
  • MSc, University of Windsor, Endocrinology. 1977
  • BSc (Hon), University of Windsor, Biology/Chemistry. 1975

Awards and Recognition

Publications

Bondy, Greg PUBMED

Selected Publications

Research
OpenClose

Research Interest

HIV/AIDS, HIV, Addictions & Related Diseases

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Clinical Teaching

Bruyère, Helene

Bruyère, Helene

MD

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Medical Director, VGH Cytogenetics Laboratory

Affiliation(s): VGH/VCHRI

Research and Scholarly Interests: Cancer, Genetics Genomics Proteomics and Related Approaches, Reproduction & Healthy Pregnancy, Clinical Research of Phenotype-Genotype Relationships for Chromosome Abnormalities, Clinical Genetics

Clinical Interests:

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • MSc, University of Lyon, Biological and Medical Engineering. 1992
  • Master of Biological and Medical Sciences (MSBM), University of Lyon, Hematology, Genetics and Cytogenetics Certificates. 1991
  • MD, Faculty of Medicine, University of Saint-Etienne, France. 1989

Awards and Recognition

Publications

Bruyère, Helene PUBMED

Selected Publications

Research
OpenClose

Research Interest

Reproduction & Healthy Pregnancy, Clinical research of phenotype-genotype relationships for chromosome abnormalities, especially those detected prenatally, Clinical genetics

Summary: As a cytogeneticist, I am interested in understanding how rare chromosome abnormalities affect human health. Many abnormalities can be detected prenatally. When an abnormality is detected prenatally, the outcome for the child can be dramatically different from what is expected from the postnatal case descriptions. Studies of series of fetuses or newborn babies that have the same cytogenetic abnormality provide information that is irreplaceable for appropriate genetic counselling. The studies also aim to provide recommendations for cytogenetic analysis and to ensure accuracy of cytogenetic diagnosis.

Clinical Service

Current Projects In My Lab Include

  • Trisomy is extremely frequent in humans at conception, affecting about 4% of clinically recognized pregnancies. Most trisomic conceptuses are lost in the first trimester. However, some trisomic pregnancies proceed to term, and one of the mechanisms thought to play a role is chromosome mosaicism. Because the distribution of the trisomic cell line typically appears random, and the clinical consequences vary from case to case, a prenatal finding of mosaicism raises counselling issues. By extensively studying cases of fetal trisomy mosaicism and reviewing the literature, we will determine whether patterns of distribution can be found that will enhance the understanding of and counselling for cases of prenatally detected trisomy mosaicism.Sex chromosome abnormalities occur in approximately 0.2% of live births. Common sex chromosome anomalies such as 45,X, 47,XXY, 47,XXX, and 47,XYY are well described and associated for the most part with predictable phenotypes. However, rare sex chromosome abnormalities often are limited to individual case reports, raising the possibility of inaccurate phenotype prediction due to biased ascertainment. An isodicentric chromosome for the short arm of the Y chromosome (idic Yp) is associated with a wide range of phenotypes in postnatally ascertained cases. It has been reported in females with either Turner syndrome or with short stature alone, children with ambiguous genitalia, boys with mental retardation and craniofacial abnormalities or short stature and incomplete masculinization, a male with short stature and schizophrenia, infertile men with short stature, and phenotypically normal males with infertility. Reports of prenatally diagnosed cases of idic Yp are rare and have limited patient follow-up. We plan to present the prenatal cytogenetic findings and postnatal outcomes of a series of idic Yp cases, to review the literature, and to provide recommendations for cytogenetic analysis and counselling.
Teaching
OpenClose

Teaching Interest

Champagne, Sylvie

Portrait photo of Sylvie  Champagne

Champagne, Sylvie

MD, (Univ Of Sherbrooke, Quebec), FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC | Medical Microbiologist, Providence Health Care

Affiliation(s): St. Paul’s Hospital

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Pediatric Infectious Diseases, MRSA, C.difficile

Clinical Interests:

Short Bio
OpenClose

Born and raised in “La belle province” of Québec, I obtained my M.D. from Université de Sherbrooke. Following graduation I pursued an internship in Pediatrics at Université Laval in Québec City. I then completed my Pediatric residency with three years at Hospital for Sick Children in Toronto, including a fellowship in Pediatric Infectious Diseases. My interest in Pediatric Infectious Diseases brought me to Vancouver to complete a research fellowship at BC Children’s Hospital followed by another residency program in Medical Microbiology at University of British Columbia. I have worked in various sites in Vancouver including community laboratory, VGH, BCCDC and currently at Providence Health Care as Medical Microbiologist for the past 12 years. I have been involved in Medical Education as Program Director and Site Director for Medical Microbiology Residency Training Committee. I was recipient of the Resident Teaching Appreciation Award by Medical Microbiology residents (2010-2011). I also served as Board examiner in Medical Microbiology for Royal College of Physicians and Surgeons for five years.

 

Academic
OpenClose

Academic Background

  • FRCPC – Medical Microbiology. 1987
  • FRCPC – Paediatrics. 1983
  • Corporation Professionelle des Medecins du Quebec – Specialiste en pediatrie. 1983
  • LMCC. 1979
  • MD, Universite de Sherbrooke. 1978

Awards and Recognition

Publications

Champagne, Sylvie PUBMED

Selected Publications

Research
OpenClose

Research Interest

  • Pediatric Infectious Diseases
  • MRSA
  • C.difficile

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Chipperfield, Kate

Chipperfield, Kate

MD, FRCP

Academic Rank(s): Clinical Professor, UBC, Department of Pathology and Laboratory Medicine | Head, Division of Hematopathology, BC Children’s Hospital

Affiliation(s): BCCH / BCCHRI

Research and Scholarly Interests: Hematology changes during pregnancy and peripartum, Pediatric and perinatal blood transfusion and hematology laboratory testing, transfusion medicine

Clinical Interests: Hematopathology, specifically within the pediatric and perinatal populations. Transfusion medicine, particularly in the context of pediatric and perinatal care. Education and quality improvement in hematology, transfusion medicine, and laboratory testing.​

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • Fellow of the Royal College of Physicians and Surgeons of Canada, Hematological Pathology. 2003
  • Royal College of Physicians and Surgeons of Canada, Certificate of Special Competence in Hematology. 2001
  • Fellow of the Royal College of Physicians and Surgeons of Canada, Internal Medicine. 2000

Awards and Recognition

  • Melvyn Bernstein Resident Teaching Award, UBC Dept of Pathology Residents, 2019
  • Award for Excellence in Clinical Service, UBC Dept of Pathology and Laboratory Medicine, 2011
  • Faculty of Medicine Clinical Excellence in Teaching Award, UBC. May 2007
  • Education Award for Excellence, UBC Dept of Pathology & Laboratory Medicine, May 2007
  • Master Teacher Award (Hematology/Transfusion Medicine), UBC Anesthesia Residents 2006

Publications

Pubmed

Research
OpenClose

Research Interest

  • Pediatric and Perinatal blood transfusion and hematology laboratory testing
  • Patient safety and quality

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

  • Undergraduate Medical and Post-Graduate training in Transfusion Medicine, Hematology and Hematopathology. [See teaching statement below]
  • Creation, implementation and coordination of a recurring dedicated one-month Transfusion Medicine Rotation for General Pathology, Hematopathology and Hematology Residents, UBC, PATH 704 (0).

Teaching Statement

My focus in undergraduate and post-graduate medical education is Hematological Pathology and Transfusion Medicine. The majority of my teaching efforts are focused in the hematopathology, pediatric hematology/oncology, and clinical hematology residency programs.   As a hematopathologist participating in sign-out duties at BC Children’s Hospital, I teach residents and medical students around the microscope whenever I am on service.

In a structured setting I teach using a combination of didactic lecture and case scenarios. Such an approach allows the physician in-training to process necessary background knowledge around a topic and then apply it in a practical manner. In this way, key points critical for effective hematology or transfusion practices are reiterated. Within the rotations I coordinate or mentor, questions, discussions, and trainee-driven literature reviews and teaching are encouraged. Whenever possible, clinical cases or teaching points are illustrated using digital photos, related blood films, bone marrow films, or serologic methods and reactions.

A major part of achieving quality in transfusion medicine and laboratory hematology is ensuring that medical students, residents, physicians and nurses understand indications for lab testing, product transfusion, correct administration of product, recognition and management of adverse transfusion events, and correct interpretation of laboratory hematology testing. To this end, I teach not only medical students and residents in organized sessions, but practicing physicians and nurses by day to day interactions, and by developing systematic education or process improvements.

I believe in guiding literature-based, and trainee-driven learning toward practical lessons applicable to everyday patient care scenarios.

Denegri, Jorge

Denegri, Jorge

MD (Univ Of Buenos Aires), FRCPC

Academic Rank(s): Clinical Associate Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s): Laurel Medical Centre

Research and Scholarly Interests: Infectious Diseases and Immunology Microbiology, Cellular Immunology and Transplantation, Immunotherapy, Immunoregulation, Cryopreservation and autologous bone marrow transplantation, Tissue Typing and immunogenetics, Clinical Hematology

Clinical Interests:

Short Bio
OpenClose

 

Academic
OpenClose

Academic Background

  • FRCP(C) Hematology. 1980
  • MD, Medico – University of Buenos Aires, Argentina. 1970

Awards and Recognition

Publications

Selected Publications

  • Keown PA, Stawecki M, McMichael J, Koegler J, Freeman D, Grant DR, Wall W, McKenzie FN, Stiller CR, Cameron E, Yeung K, Shackleton C, Glenn J, Denegri JF. Therapeutic monitioring of cyclosporine: Analytical and clinical considerations in the evolution to a whole-blood matrix using a selective monoclonal assay. Transplant. Proc.. 2004
  • Keown PA, Gleen J, Denegri JF, Deeg HJ, Seccombe D. Therapeutic monitoring of cyclosporine: Comparison of serum and whole-blooded standard curves in the 125I-labelled monoclonal radioimmunoassay. Clin. Chem. . 2004.
  • Sherlock C, Genegri JF, et al: CMV infection in kidney tansplantation. Prognosite significance and comparison between western blotting, complement consumption and immunofluorescent techniques. 2004
  • Sherlock CH, Denegri JF, Ashley RL. Serological responses to cytomegalovirus during renal transplant rejection. Transplantation. 52:272-275, 1991.
Research
OpenClose

Research Interest

  • Cellular Immunology and Transplantation
  • Immunotherapy in acute leukemia and other tumors with in vitro stimulated lymphocytes against autologous malignant cells – host vs tumor effect
  • Immunoregulation in autoimmune diseases
  • Cryopreservation and autologous bone marrow transplantation
  • Tissue Typing and immunogenetics
  • Clinical Hematology

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Dunham, Christopher

Dunham, Christopher

BSc, MD, FRCPC

Academic Rank(s): Clinical Associate Professor, Pathology and Laboratory Medicine, UBC | Investigator, BC Children’s Hospital

Affiliation(s): BCCH/BCCHRI

Research and Scholarly Interests: Brain and Neuroscience, Cancer, Pediatric Brain Neoplasia, CNS Malformations, Hypoxic Ischemic Injury

Clinical Interests:

Short Bio
OpenClose

Born and raised in Edmonton, Alberta, Dr. Dunham received his BSc in Science Psychology at the U of Alberta after which he obtained his MD from the U of Ottawa in 2001. His interest in Neuropathology was peaked by an early mentor, Dr. Vital Montpetit, Neuropathologist at Ottawa General Hospital. Dr. Dunham completed his residency training in Neuropathology at the U of Calgary under the tutelage of Drs. Bernadette Curry, Arthur Clark and Roland Auer. Upon graduation in 2006, Dr. Dunham spent a year of fellowship training in Molecular Neuropathology under the guidance of Dr. Arie Perry at Washington University in St. Louis, MO, USA. After completing his fellowship in June of 2007, and after spending a summer Neuropathology locum at the University of Saskatoon, Dr. Dunham joined the Dept of Path and Lab Med, Div of AP at C&W’s hospital in October of 2007. He is a full time Neuropathologist with interest in all areas of neuropathology including neuro-oncology.

 

Academic
OpenClose

Academic Background

  • MD University of Ottawa, Ottawa, ON, Canada. 2001
  • BSc with Specialization in Psychology, University of Alberta, Edmonton, AB, Canada. 1996

Professional Qualifications

  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC), Neuropathology. Jun 2006
  • Licentiate of the Medical Council of Canada (LMCC); Part I, June 2001; Part II.  Oct 2002

Awards and Recognition

Publications

Selected Publications

Research
OpenClose

Research Interest

  • Pediatric Brain Neoplasia
  • CNS Malformations
  • Hypoxic Ischemic Injury

As a pediatric Neuropathologist, I am charged with the diagnosis and study of diseases of the nervous system in children. I examine abnormal tissues that are sampled from patients undergoing surgery or autopsy. These clinically derived tissues form the basis of my laboratory based practice and largely guide my research. Chiefly via microscopy, I am able to distinguish the culprit disease process(es) that is(are) affecting a patient; in turn, this information is then relayed to the primary care clinicians (eg, neurologists, neurosurgeons, oncologists etc.) and used to guide patient care.

One form of brain cancer has particularly captured my attention: Atypical Teratoid Rhabdoid Tumor (ATRT). My research into ATRT is aimed at re-examining BCCH’s experience with this tumor and using this information to guide the treatment of future patients. In addition, in a BCCH Telethon funded project, I am investigating the microscopy and genetics of Anencephaly, most common congenital brain malformation which is considered to reside amongst the ‘neural tube disorders’.

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

Pediatric Neuropathology; CNS Tumors

English, John

English, John

BSc(Hon) MD FRCPC

Academic Rank(s): Clinical Professor, Pathology and Laboratory Medicine, UBC

Affiliation(s):VGH/VCHRI

Research and Scholarly Interests: Cardiovascular and Pulmonary

Clinical Interests:

Short Bio
OpenClose

Dr. John English qualified in medicine at the University of Calgary in 1984 and obtained his Fellowship in Anatomical Pathology from the University of Western Ontario in 1990. He has since worked at the Vancouver General Hospital, in the Division of Anatomical Pathology, for a time as Division Head.

Dr. English entered practise as a cardiovascular pathologist but, to fill an important clinical demand, became involved in the pulmonary pathology service in 1995. He is currently Consultant Pathologist and Discipline Lead, Cardiothoracic Pathology, VGH, Associate Member of the Division of Respiratory Medicine, UBC and recently appointed as Clinical Professor of Pathology.

Dr. English is active in teaching at all levels of undergraduate and post-graduate medicine and has given courses at national meetings. His research interests include the molecular basis of lung cancer, interstitial lung disease and radiological-pathological correlation in thoracic medicine.

 

Academic
OpenClose

Academic Background

  • MD, University of Calgary. 1984
  • BSc(Hon), University of Western Ontario, Biology. 1978

 

Professional Qualifications

  • FRCP Certificate in Anatomic Pathology – L.M.C.C., Ontario. 1990
  • Residency training, University of Western Ontario, Department of Pathology (Anatomical Pathology). 1985-1990
  • Internship – Surgery , University of Western Ontario (Victoria Hospital/University Hospital). 1984-1985
  • MSc Program – Anatomy (withdrew to enter medicine), University of Calgary. 1978-1981
  • Medical License – Licentiate of the Medical Council of Canada (LMCC)
  • Medical License – College of Physicians and Surgeons of British Columbia

Awards and Recognition

Publications

Selected Publications

  • Ishii T, Abboud RT, Wallace AM, English JC, Coxson HO, Finley RJ, Shumansky K, Paré PD, Sandford AJ. Alveolar macrophage proteinase/antiproteinase expression and lung function/emphysema. ERJ (2014); 43:82-91.
  • Wallace AM, Loy LB, Abboud RT, D’Armiento JM, Coxson HO, Muller NL, Kalloger S, Li X, Elliott WM, English JC, Finley RJ, Paré PD. Expression of matrix metalloproteinase-1 in alveolar macrophages, type II pneumocytes, and airways in smokers: relationship to lung function and emphysema. Lung (2014); DOI 10.1007/s00408-014-9585-6.
  • Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao M-S, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnson MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz J-C, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ. Resource utilization and costs durin 2014
  • Lee AMD, Kirby M, Ohtani K, Candido T, Shalansky R, MacAulay C, English J, Finley R, Lam S, Coxson H, Lane P. Validation of airway wall measurements by optical coherence tomography in porcine airways. PloS One 2014; 9(6) e10145. doi:10.1371/journal.pone.0100145.
  • Finley RJ, ….Preoperative CT-Guided Microcoil Localization of Small Peripheral Pulmonary Nodules: A Prospective Randomized Controlled Trial. J Thorac Cardiovasc Surg 2014; in press.
  • Gleeson T, Thiessen R, Hannigan A, English JC, Müller NL, Mayo JR. Pulmonary Hamartomas: CT Pixel Analysis for Fat Attenuation using Radiologic-Pathologic correlation. JMIRO 2013 (in press) Article first published online: 4 JUN 2013 | DOI: 10.1111/1754-9485.12083.
  • Wright AJ, Steiner T, Bilawich A-M, English JC, Ryan CF. Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab. (2013) Can J Infect Dis Med Microbiol 24: 67-68.
  • McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M, Atkar-Khattra S, Berg CD, Evans K, Finley R, Yee J, English J, Nasute P, Goffin J, Puksa S, Stewart L, Tsai S, Johnston MR, Manos D, Nicholas G, Goss GD, Seely JM, Amjadi K, Tremblay A, Burrowes P, MacEachern P, Bhatia R, Tsao M-S, Lam S. Probability of cancer in pulmonary nodules detected on first screening CT. (2013) N Engl J Med 369: 910-919
  • Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offringa I-A, Liu P, Anderson M, You M, Tsao M-S, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene (2013) doi:10.1038/o
  • Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y. Elevated Expression of BIRC6 Protein in Non-Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance. J Thorac Oncol 2013; 8:161-170. DOI:10.1097/JTO.0b013e31827d5237.
Research
OpenClose

Research Interest

  • Ischemia – reperfusion injury in acute myocardial ischemia
  • Ischemia – reperfusion injury in lung transplantation
  • Tumour angiogenesis
  • Molecular biology of early lung cancer development
  • CT scan/pathology correlation of airway dimensions

Clinical Service

Current Projects In My Lab Include

Teaching
OpenClose

Teaching Interest

  • Cardiovascular pathology consultant (surgical and autopsy pathology at Vancouver hospital and Health Sciences Centre; intraprovincial cardiovascular consultation).
    Principal interests: heart transplantation, atherosclerotic heart disease and myocardial ischemia, cardiomyopathies.
  • Pulmonary pathology – principal liaison between Anatomical Pathology and Clinical Pulmonary Medicine and Surgery; in charge of organizing weekly academic clinical-pathological conference with Pulmonary Medicine/Surgery/Radiology services.
    Principal interests: pulmonary transplantation, general pulmonary pathology.
  • Director – Electron Microscopy Unit, Divison of Anatomical Pathology, Department of Pathology and Laboratory Medicine, Vancouver Hospital and Health Sciences Centre.